≡ Risteys
R14

Documentation Changelog GitHub Contact & Feedback

Benign neoplasm of soft tissue of retroperitoneum and peritoneum

DOID EFO Endpoint Browser PheWeb

CD2_BENIGN_RETROPERITONEUM_PERITONEUM

retroperitoneal cancer: An organ system cancer located_in the retroperitoneal space that is manifested in retroperitoneal space in the abdominal cavity behind the peritoneum.

Suggest a new description

Endpoint definition

↥

Report an error or suggest an improvement for this endpoint codes

Endpoint definition steps

FinnGen

Phenotype data

519870

1. Apply sex-specific rule

None

519870

2. Check conditions

None

519870

3. Check pre-conditions, main-only, mode, registry filters

Registry filters:

  • Hospital discharge: ICD-10 — D20
  • Hospital discharge: ICD-9 — 2118
  • Hospital discharge: ICD-8 — 2117
  • Cause of death: ICD-10 — D20
  • Cause of death: ICD-9 — 2118
  • Cause of death: ICD-8 — 2117

2 out of 7 registries used, show all original rules.

193

4. Check minimum number of events

None

193

5. Include endpoints

None

193

6. Filter based on genotype QC (FinnGen only)

192

Control definitions (FinnGen only)

Controls for this endpoint are individuals that are not cases.

Extra metadata

Level in the ICD hierarchy
2
First used in FinnGen datafreeze
DF2
Parent code in ICD-10
D10-D36
Name in latin
Neoplasma benignum telae mollis spatii retroperitonealis et/sive peritonei

Case counts by codes

↥

FinnGen case counts by registry codes:

generic upset plot

Upset plot

Full data table

Summary Statistics

↥

-FinRegistry-

Key figures

All Female Male
Number of individuals
Whole population 1295 851 432
Only index persons 1064 738 326
Unadjusted period prevalence (%)
Whole population 0.02 0.02 0.01
Only index persons 0.02 0.03 0.01
Median age at first event (years)
Whole population 56.26 53.03 62.62
Only index persons 53.21 50.40 59.57

-FinnGen-

Key figures

All Female Male
Number of individuals 192 140 52
Unadjusted period prevalence (%) 0.04 0.05 0.02
Median age at first event (years) 56.20 52.50 66.16

-FinRegistry-

Age distribution of first events

-FinnGen-

Age distribution of first events

-FinRegistry-

Year distribution of first events

-FinnGen-

Year distribution of first events

-FinRegistry-

Cumulative Incidence Function

-FinnGen-

Cumulative Incidence Function

No data

CodeWAS

↥

CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.

This is a new tool, please reach out using the contact form for feedback and improvement ideas.

First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.

Matched cohort

Matched cases
193
Matched controls
1930
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
D20.0
ICD-10 Finland
Benign neoplasm: Retroperitoneum
+∞
137.5
115
*
D20.1
ICD-10 Finland
Benign neoplasm: Peritoneum
+∞
61.9
56
*
D48.3
ICD-10 Finland
Neoplasm of uncertain or unknown behaviour: Retroperitoneum
234.2
21.0
21
*
R19.0
ICD-10 Finland
Intra-abdominal and pelvic swelling, mass and lump
17.2
14.8
23
15
JAH01
NOMESCO Finland
Laparoscopy
6.1
14.0
26
48
21170
ICD-8 Finland
Benign neoplasm of other parts of digestive system, Peritoneum and retroperitoneal tissue
+∞
11.6
11
*
KKB10
NOMESCO Finland
Excision of retroperitoneal tumour
127.3
11.6
12
*
WX302
NOMESCO Finland
Thoracal epidural anesthesy
5.6
11.1
22
43
JN3BD
NOMESCO Finland
Extensive abdominal CT
3.9
11.1
37
111
D20
ICD-10 Finland
Benign neoplasm of soft tissue of retroperitoneum and peritoneum
+∞
9.4
9
*
JAH00
NOMESCO Finland
Laparotomy
7.7
9.3
21
30
UJF32
NOMESCO Finland
Coloscopy
2.5
8.1
68
343
2118X
ICD-9 Finland
Benign neoplasm of other parts of digestive system, Retroperitoneum and peritoneum[NEOPLASMA BENIGNUM ALIUD SPATII RETROPERITON ET PER]
+∞
7.3
7
*
UKC02
NOMESCO Finland
Cystoscopy
2.8
7.3
41
168
N13.3
ICD-10 Finland
Other and unspecified hydronephrosis
7.5
6.3
14
20
KBV02
NOMESCO Finland
Cystoscopic insertion of stent into ureter
9.1
6.2
12
14
R10.4
ICD-10 Finland
Other and unspecified abdominal pain
2.1
6.1
85
519

TimeCodeWAS

↥

TODO / Current known limitations:

  • Only showing the top 300 codes, because showing all (sometimes 20k) makes the page too slow.
  • Legend / how to read the glyphs.
  • Show details (e.g. Fisher or Chi-square test, LR+, etc.) when clicking on a row.
  • Explanation on the underlying data / how the TimeCodeWAS is done (e.g. matched cases / controls, eligibility).
  • Download CSV.
  • No filters and sorters.
  • Limited amount of endpoints (~400) having TimeCodeWAS data.
  • Cross-links to Risteys lab test pages for lab test codes.
OMOP concept
ln(OR)
%cases with code / %controls with code
2×2 table
Outpatient Visit
OP [9202]
3.2e-01
1.3e+00
1.7e+00
5.7e+00
1.6e+00
1.7e+00
6.4e-01
cases:70.88%
controls:63.90%
cases:72.53%
controls:41.77%
cases:36.81%
controls:9.47%
cases:51.10%
controls:0.33%
cases:32.04%
controls:9.04%
cases:80.92%
controls:43.40%
cases:83.12%
controls:72.27%
129
1161
53
656
132
759
50
1058
67
172
115
1645
93
6
89
1811
58
164
123
1651
140
773
33
1008
128
1173
26
450
Upper gastrointestinal surgery
106 [44777669]
1.0e+00
2.2e+00
—
1.0e+50
3.6e+00
2.0e+00
1.3e+00
cases:15.38%
controls:6.22%
cases:17.03%
controls:2.20%
—
—
cases:26.92%
controls:0.00%
cases:11.05%
controls:0.33%
cases:18.50%
controls:2.86%
cases:23.38%
controls:8.01%
28
113
154
1704
31
40
151
1777
—
49
0
133
1817
20
6
161
1809
32
51
141
1730
36
130
118
1493
Obstetrics / Gynecology
16 [38004461]
5.1e-01
1.5e+00
2.6e+00
—
2.7e+00
1.7e+00
4.6e-01
cases:25.82%
controls:17.23%
cases:23.63%
controls:6.27%
cases:10.44%
controls:0.88%
—
—
cases:10.50%
controls:0.77%
cases:22.54%
controls:5.28%
cases:19.48%
controls:13.25%
47
313
135
1504
43
114
139
1703
19
16
163
1801
—
19
14
162
1801
39
94
134
1687
30
215
124
1408
General Surgery
2 [38004447]
2.3e-01
1.3e+00
3.1e+00
1.0e+50
2.2e+00
1.4e+00
2.8e-01
cases:24.73%
controls:20.69%
cases:21.43%
controls:6.77%
cases:12.09%
controls:0.61%
cases:21.43%
controls:0.00%
cases:8.29%
controls:0.99%
cases:21.39%
controls:6.57%
cases:25.32%
controls:20.33%
45
376
137
1441
39
123
143
1694
22
11
160
1806
39
0
143
1817
15
18
166
1797
37
117
136
1664
39
330
115
1293
Outpatient Hospital
22 [8756]
4.7e-01
1.4e+00
2.3e+00
—
2.6e+00
1.6e+00
3.9e-01
cases:34.07%
controls:24.38%
cases:24.73%
controls:7.26%
cases:6.04%
controls:0.66%
—
—
cases:8.29%
controls:0.66%
cases:26.01%
controls:6.51%
cases:28.57%
controls:21.38%
62
443
120
1374
45
132
137
1685
11
12
171
1805
—
15
12
166
1803
45
116
128
1665
44
347
110
1276
Inpatient Hospital
21 [8717]
3.3e-01
1.1e+00
2.4e+00
—
2.4e+00
1.4e+00
2.1e-01
cases:39.01%
controls:31.54%
cases:29.12%
controls:12.27%
cases:12.64%
controls:1.27%
—
—
cases:14.92%
controls:1.60%
cases:30.64%
controls:9.83%
cases:33.77%
controls:29.21%
71
573
111
1244
53
223
129
1594
23
23
159
1794
—
27
29
154
1786
53
175
120
1606
52
474
102
1149
Albumin [Mass/volume] in Serum or Plasma
1751-7 [3024561]
9.1e-01
1.3e+00
2.5e+00
—
—
1.4e+00
6.0e-01
cases:10.99%
controls:4.73%
cases:8.24%
controls:2.48%
cases:4.95%
controls:0.44%
—
—
—
—
cases:7.51%
controls:1.91%
cases:12.34%
controls:7.15%
20
86
162
1731
15
45
167
1772
9
8
173
1809
—
—
13
34
160
1747
19
116
135
1507
Laboratory Visit
OMOP4822461 [32036]
8.1e-02
2.2e-01
1.3e+00
3.3e+00
8.1e-01
2.1e-01
9.2e-02
cases:25.27%
controls:23.78%
cases:26.37%
controls:22.29%
cases:19.78%
controls:6.38%
cases:7.14%
controls:0.28%
cases:13.81%
controls:6.67%
cases:28.90%
controls:24.87%
cases:40.91%
controls:38.69%
46
432
136
1385
48
405
134
1412
36
116
146
1701
13
5
169
1812
25
121
156
1694
50
443
123
1338
63
628
91
995
Supplier / Service Provider
OMOP5117446 [33004]
-8.5e-01
-5.3e-01
—
—
—
3.2e+00
3.0e+00
cases:12.09%
controls:24.27%
cases:5.49%
controls:9.03%
—
—
—
—
—
—
cases:6.36%
controls:0.28%
cases:10.39%
controls:0.55%
22
441
160
1376
10
164
172
1653
—
—
—
11
5
162
1776
16
9
138
1614
Parkinson disease
G20 [45538098]
2.0e+00
2.5e+00
—
—
—
2.4e+00
—
cases:2.75%
controls:0.39%
cases:4.40%
controls:0.39%
—
—
—
—
—
—
cases:3.47%
controls:0.34%
—
—
5
7
177
1810
8
7
174
1810
—
—
—
6
6
167
1775
—
Emergency Room Visit
ER [9203]
3.0e-01
1.1e+00
1.8e+00
1.0e+50
1.8e+00
6.6e-01
1.4e-01
cases:34.62%
controls:28.18%
cases:26.92%
controls:10.51%
cases:7.14%
controls:1.21%
cases:7.14%
controls:0.00%
cases:4.97%
controls:0.83%
cases:19.08%
controls:10.84%
cases:32.47%
controls:29.51%
63
512
119
1305
49
191
133
1626
13
22
169
1795
13
0
169
1817
9
15
172
1800
33
193
140
1588
50
479
104
1144
Essential (primary) hypertension
I10 [45591453]
2.8e-01
1.1e+00
1.8e+00
—
1.8e+00
8.2e-01
3.8e-01
cases:14.84%
controls:11.61%
cases:12.64%
controls:4.51%
cases:3.85%
controls:0.66%
—
—
cases:4.97%
controls:0.83%
cases:11.56%
controls:5.45%
cases:21.43%
controls:15.77%
27
211
155
1606
23
82
159
1735
7
12
175
1805
—
9
15
172
1800
20
97
153
1684
33
256
121
1367
hydroxyzine; oral, parenteral
N05BB01 [21604590]
8.5e-01
—
—
—
—
2.4e+00
1.9e+00
cases:3.30%
controls:1.43%
—
—
—
—
—
—
—
—
cases:4.05%
controls:0.39%
cases:6.49%
controls:0.99%
6
26
176
1791
—
—
—
—
7
7
166
1774
10
16
144
1607
Case Management Agency
251B00000X [38004193]
1.1e-01
1.7e-01
6.2e-01
3.0e+00
6.6e-01
3.9e-01
-4.7e-02
cases:47.25%
controls:44.47%
cases:42.31%
controls:38.30%
cases:25.27%
controls:15.35%
cases:15.93%
controls:0.94%
cases:24.86%
controls:14.66%
cases:50.29%
controls:40.76%
cases:59.74%
controls:60.87%
86
808
96
1009
77
696
105
1121
46
279
136
1538
29
17
153
1800
45
266
136
1549
87
726
86
1055
92
988
62
635
paracetamol; oral, parenteral, rectal
N02BE01 [21604344]
3.4e-01
6.5e-01
1.9e+00
—
1.4e+00
7.9e-01
3.7e-01
cases:31.32%
controls:24.44%
cases:20.33%
controls:11.78%
cases:12.09%
controls:1.98%
—
—
cases:7.73%
controls:2.04%
cases:24.86%
controls:13.03%
cases:39.61%
controls:31.12%
57
444
125
1373
37
214
145
1603
22
36
160
1781
—
14
37
167
1778
43
232
130
1549
61
505
93
1118
Thorax X-ray examination
GD1AA [2001303617]
3.7e-01
1.4e+00
—
—
—
1.5e+00
1.1e+00
cases:5.49%
controls:3.85%
cases:6.04%
controls:1.49%
—
—
—
—
—
—
cases:6.94%
controls:1.68%
cases:16.23%
controls:5.79%
10
70
172
1747
11
27
171
1790
—
—
—
12
30
161
1751
25
94
129
1529
Medical doctor
Z2221 [2001311556]
3.2e-01
1.9e+00
—
1.0e+50
—
2.1e+00
1.1e+00
cases:4.95%
controls:3.63%
cases:7.14%
controls:1.16%
—
—
cases:2.75%
controls:0.00%
—
—
cases:5.78%
controls:0.73%
cases:7.14%
controls:2.53%
9
66
173
1751
13
21
169
1796
—
5
0
177
1817
—
10
13
163
1768
11
41
143
1582
Bilirubin.total [Moles/volume] in Serum or Plasma
14631-6 [3006140]
7.2e-01
1.3e+00
2.6e+00
—
1.8e+00
1.0e+00
6.2e-01
cases:9.89%
controls:5.06%
cases:9.89%
controls:2.97%
cases:4.95%
controls:0.39%
—
—
cases:3.31%
controls:0.55%
cases:7.51%
controls:2.86%
cases:15.58%
controls:9.00%
18
92
164
1725
18
54
164
1763
9
7
173
1810
—
6
10
175
1805
13
51
160
1730
24
146
130
1477
Transvaginal ultrasound examination of uterus, parametria and lower abdomen
LC2BE [2001306544]
6.5e-01
1.7e+00
—
—
—
2.1e+00
8.4e-01
cases:7.14%
controls:3.85%
cases:7.14%
controls:1.38%
—
—
—
—
—
—
cases:7.51%
controls:1.01%
cases:8.44%
controls:3.82%
13
70
169
1747
13
25
169
1792
—
—
—
13
18
160
1763
13
62
141
1561
ABO and Rh group [Type] in Blood by Confirmatory method
77397-8 [46236098]
6.7e-01
1.6e+00
—
—
—
2.1e+00
1.1e+00
cases:4.95%
controls:2.59%
cases:4.40%
controls:0.88%
—
—
—
—
—
—
cases:8.09%
controls:1.07%
cases:7.79%
controls:2.71%
9
47
173
1770
8
16
174
1801
—
—
—
14
19
159
1762
12
44
142
1579
Other and unspecified abdominal pain
R10.4 [45568113]
3.0e-01
1.9e+00
—
—
—
1.8e+00
9.3e-01
cases:6.04%
controls:4.57%
cases:8.79%
controls:1.43%
—
—
—
—
—
—
cases:8.09%
controls:1.40%
cases:11.04%
controls:4.68%
11
83
171
1734
16
26
166
1791
—
—
—
14
25
159
1756
17
76
137
1547
Glucose [Moles/volume] in Serum or Plasma
14749-6 [3013826]
5.0e-01
1.1e+00
2.5e+00
—
—
6.7e-01
4.9e-01
cases:9.89%
controls:6.22%
cases:8.24%
controls:2.81%
cases:4.40%
controls:0.39%
—
—
—
—
cases:6.36%
controls:3.37%
cases:14.29%
controls:9.24%
18
113
164
1704
15
51
167
1766
8
7
174
1810
—
—
11
60
162
1721
22
150
132
1473
Scheduled procedure
ZXD10 [2001311387]
5.2e-01
1.4e+00
—
1.0e+50
—
2.1e+00
6.7e-01
cases:8.24%
controls:5.06%
cases:7.14%
controls:1.82%
—
—
cases:4.95%
controls:0.00%
—
—
cases:9.83%
controls:1.35%
cases:8.44%
controls:4.50%
15
92
167
1725
13
33
169
1784
—
9
0
173
1817
—
17
24
156
1757
13
73
141
1550
Folate [Moles/volume] in Red Blood Cells
14731-4 [3019309]
1.4e+00
2.0e+00
—
—
—
—
—
cases:5.49%
controls:1.43%
cases:3.30%
controls:0.44%
—
—
—
—
—
—
—
—
—
—
10
26
172
1791
6
8
176
1809
—
—
—
—
—
INR in Blood by Coagulation assay
34714-6 [3032080]
2.7e-01
1.2e+00
1.7e+00
—
2.1e+00
8.6e-01
5.8e-01
cases:5.49%
controls:4.24%
cases:7.14%
controls:2.20%
cases:3.30%
controls:0.61%
—
—
cases:4.42%
controls:0.55%
cases:5.78%
controls:2.53%
cases:12.34%
controls:7.33%
10
77
172
1740
13
40
169
1777
6
11
176
1806
—
8
10
173
1805
10
45
163
1736
19
119
135
1504
C reactive protein [Mass/volume] in Serum or Plasma
1988-5 [3020460]
1.6e-01
6.8e-01
1.7e+00
—
1.6e+00
4.9e-01
4.4e-01
cases:18.68%
controls:16.40%
cases:18.68%
controls:10.46%
cases:10.44%
controls:2.04%
—
—
cases:7.73%
controls:1.71%
cases:16.76%
controls:10.95%
cases:33.77%
controls:24.77%
34
298
148
1519
34
190
148
1627
19
37
163
1780
—
14
31
167
1784
29
195
144
1586
52
402
102
1221
tramadol; oral, parenteral, rectal
N02AX02 [21604298]
4.1e-01
7.4e-01
—
—
2.0e+00
1.3e+00
7.7e-01
cases:9.34%
controls:6.38%
cases:4.40%
controls:2.15%
—
—
—
—
cases:3.87%
controls:0.55%
cases:7.51%
controls:2.19%
cases:13.64%
controls:6.84%
17
116
165
1701
8
39
174
1778
—
—
7
10
174
1805
13
39
160
1742
21
111
133
1512
Coloscopy
UJF32 [2001305029]
6.3e-01
1.6e+00
—
—
—
1.6e+00
9.1e-01
cases:4.95%
controls:2.70%
cases:6.04%
controls:1.32%
—
—
—
—
—
—
cases:5.20%
controls:1.07%
cases:8.44%
controls:3.57%
9
49
173
1768
11
24
171
1793
—
—
—
9
19
164
1762
13
58
141
1565
Internal Medicine
11 [38004456]
2.8e-01
1.0e+00
1.4e+00
—
1.2e+00
7.7e-01
6.1e-01
cases:25.27%
controls:20.36%
cases:21.43%
controls:9.08%
cases:5.49%
controls:1.43%
—
—
cases:4.42%
controls:1.43%
cases:17.34%
controls:8.87%
cases:30.52%
controls:19.29%
46
370
136
1447
39
165
143
1652
10
26
172
1791
—
8
26
173
1789
30
158
143
1623
47
313
107
1310
Creatinine [Moles/volume] in Serum or Plasma
14682-9 [3020564]
2.4e-01
4.9e-01
2.0e+00
—
1.2e+00
3.5e-01
2.4e-01
cases:23.08%
controls:19.10%
cases:21.98%
controls:14.75%
cases:15.38%
controls:2.48%
—
—
cases:9.94%
controls:3.36%
cases:21.97%
controls:16.62%
cases:36.36%
controls:31.12%
42
347
140
1470
40
268
142
1549
28
45
154
1772
—
18
61
163
1754
38
296
135
1485
56
505
98
1118
Plastic And Reconstructive Surgery
24 [38004467]
1.9e-01
1.3e+00
—
—
—
1.9e+00
1.2e+00
cases:3.30%
controls:2.75%
cases:3.85%
controls:1.05%
—
—
—
—
—
—
cases:5.20%
controls:0.84%
cases:8.44%
controls:2.83%
6
50
176
1767
7
19
175
1798
—
—
—
9
15
164
1766
13
46
141
1577
Blood group antibody screen [Presence] in Serum or Plasma
890-4 [3001079]
3.6e-01
1.2e+00
—
—
—
1.7e+00
6.4e-01
cases:7.69%
controls:5.50%
cases:7.14%
controls:2.31%
—
—
—
—
—
—
cases:9.83%
controls:1.91%
cases:11.69%
controls:6.53%
14
100
168
1717
13
42
169
1775
—
—
—
17
34
156
1747
18
106
136
1517
Ultrasound examination of uterus and parametria
LC2AE [2001306543]
1.4e+00
2.8e+00
—
—
—
—
1.5e+00
cases:2.75%
controls:0.66%
cases:4.40%
controls:0.28%
—
—
—
—
—
—
—
—
cases:3.90%
controls:0.86%
5
12
177
1805
8
5
174
1812
—
—
—
—
6
14
148
1609
prednisolone; oral, parenteral
H02AB06 [21602734]
4.3e-01
5.4e-01
1.2e+00
—
1.9e+00
4.6e-01
8.4e-01
cases:13.74%
controls:9.41%
cases:7.14%
controls:4.29%
cases:2.75%
controls:0.88%
—
—
cases:3.87%
controls:0.61%
cases:6.94%
controls:4.49%
cases:19.48%
controls:9.49%
25
171
157
1646
13
78
169
1739
5
16
177
1801
—
7
11
174
1804
12
80
161
1701
30
154
124
1469
prednisolone
A07EA01 [21600653]
4.2e-01
5.3e-01
1.2e+00
—
1.9e+00
4.5e-01
8.3e-01
cases:13.74%
controls:9.47%
cases:7.14%
controls:4.35%
cases:2.75%
controls:0.88%
—
—
cases:3.87%
controls:0.61%
cases:6.94%
controls:4.55%
cases:19.48%
controls:9.55%
25
172
157
1645
13
79
169
1738
5
16
177
1801
—
7
11
174
1804
12
81
161
1700
30
155
124
1468
Pharmacy visit
OMOP4822462 [581458]
2.6e-01
5.8e-01
6.1e-01
1.4e+00
6.9e-01
6.5e-01
5.4e-01
cases:92.31%
controls:90.26%
cases:87.36%
controls:79.53%
cases:57.69%
controls:42.65%
cases:7.14%
controls:1.87%
cases:59.12%
controls:41.98%
cases:89.60%
controls:81.86%
cases:96.75%
controls:94.58%
168
1640
14
177
159
1445
23
372
105
775
77
1042
13
34
169
1783
107
762
74
1053
155
1458
18
323
149
1535
5
88
Urology
34 [38004474]
1.1e+00
1.3e+00
—
—
—
1.5e+00
8.7e-01
cases:8.24%
controls:2.92%
cases:5.49%
controls:1.54%
—
—
—
—
—
—
cases:9.25%
controls:2.13%
cases:9.74%
controls:4.31%
15
53
167
1764
10
28
172
1789
—
—
—
16
38
157
1743
15
70
139
1553
Thorax X-ray examination outside radiological department
GD1UA [2001303652]
-1.0e+50
—
—
—
—
2.5e+00
—
cases:0.00%
controls:0.83%
—
—
—
—
—
—
—
—
cases:3.47%
controls:0.28%
—
—
0
15
182
1802
—
—
—
—
6
5
167
1776
—
Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma
6768-6 [3035995]
5.3e-01
8.8e-01
1.7e+00
—
1.4e+00
6.6e-01
6.3e-01
cases:16.48%
controls:10.40%
cases:15.93%
controls:7.26%
cases:5.49%
controls:1.10%
—
—
cases:4.42%
controls:1.16%
cases:11.56%
controls:6.34%
cases:25.32%
controls:15.34%
30
189
152
1628
29
132
153
1685
10
20
172
1797
—
8
21
173
1794
20
113
153
1668
39
249
115
1374
Extensive body CT
JN4BD [2001310899]
1.7e+00
—
—
—
—
—
2.5e+00
cases:3.30%
controls:0.61%
—
—
—
—
—
—
—
—
—
—
cases:5.19%
controls:0.43%
6
11
176
1806
—
—
—
—
—
8
7
146
1616
Cystoscopy
UKC02 [2001306005]
1.4e+00
2.5e+00
—
—
—
1.3e+00
—
cases:4.95%
controls:1.27%
cases:3.30%
controls:0.28%
—
—
—
—
—
—
cases:2.89%
controls:0.84%
—
—
9
23
173
1794
6
5
176
1812
—
—
—
5
15
168
1766
—
IgG [Mass/volume] in Serum or Plasma
2465-3 [3005719]
2.5e+00
—
—
—
—
2.0e+00
1.0e+00
cases:5.49%
controls:0.50%
—
—
—
—
—
—
—
—
cases:2.89%
controls:0.39%
cases:3.25%
controls:1.17%
10
9
172
1808
—
—
—
—
5
7
168
1774
5
19
149
1604
Inpatient Visit
IP [9201]
4.5e-01
3.3e-01
—
1.0e+50
—
1.4e+00
1.0e+00
cases:7.14%
controls:4.68%
cases:2.75%
controls:1.98%
—
—
cases:5.49%
controls:0.00%
—
—
cases:6.94%
controls:1.80%
cases:11.04%
controls:4.31%
13
85
169
1732
5
36
177
1781
—
10
0
172
1817
—
12
32
161
1749
17
70
137
1553
Giving the first information
R2110 [2001310194]
—
—
—
—
—
—
2.4e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:3.90%
controls:0.37%
—
—
—
—
—
—
6
6
148
1617
Lactate dehydrogenase [Enzymatic activity/volume] in Serum or Plasma by Lactate to pyruvate reaction
14804-9 [3022250]
—
—
—
—
—
2.4e+00
1.1e+00
—
—
—
—
—
—
—
—
—
—
cases:3.47%
controls:0.34%
cases:4.55%
controls:1.54%
—
—
—
—
—
6
6
167
1775
7
25
147
1598
IgM [Mass/volume] in Serum or Plasma
2472-9 [3028026]
2.3e+00
—
—
—
—
—
—
cases:3.85%
controls:0.39%
—
—
—
—
—
—
—
—
—
—
—
—
7
7
175
1810
—
—
—
—
—
—
levofloxacin; inhalant, oral, parenteral
J01MA12 [21603019]
—
2.2e+00
—
—
—
—
3.9e-01
—
—
cases:3.85%
controls:0.44%
—
—
—
—
—
—
—
—
cases:3.25%
controls:2.22%
—
7
8
175
1809
—
—
—
—
5
36
149
1587
Cardiology
6 [38004451]
2.9e-01
8.9e-01
2.2e+00
—
—
7.5e-01
1.5e-01
cases:7.14%
controls:5.45%
cases:7.69%
controls:3.30%
cases:3.30%
controls:0.39%
—
—
—
—
cases:5.78%
controls:2.81%
cases:9.74%
controls:8.50%
13
99
169
1718
14
60
168
1757
6
7
176
1810
—
—
10
50
163
1731
15
138
139
1485
Carcinoembryonic Ag [Mass/volume] in Serum or Plasma
2039-6 [3003785]
—
2.1e+00
—
—
—
—
1.0e+00
—
—
cases:4.95%
controls:0.61%
—
—
—
—
—
—
—
—
cases:3.25%
controls:1.17%
—
9
11
173
1806
—
—
—
—
5
19
149
1604
Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI)/1.73 sq M
62238-1 [40764999]
2.4e-01
5.7e-01
2.1e+00
—
1.0e+00
5.7e-01
3.7e-01
cases:17.58%
controls:14.31%
cases:17.03%
controls:10.40%
cases:12.09%
controls:1.60%
—
—
cases:6.08%
controls:2.31%
cases:17.92%
controls:11.01%
cases:27.92%
controls:21.07%
32
260
150
1557
31
189
151
1628
22
29
160
1788
—
11
42
170
1773
31
196
142
1585
43
342
111
1281
FEV1 --post bronchodilation
20155-8 [3023550]
—
—
—
—
—
—
2.1e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:3.90%
controls:0.49%
—
—
—
—
—
—
6
8
148
1615
FEV1 percent change
69983-5 [42868472]
—
—
—
—
—
—
2.1e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:3.90%
controls:0.49%
—
—
—
—
—
—
6
8
148
1615
Forced vital capacity [Volume] Respiratory system --post bronchodilation
19875-4 [3001668]
—
—
—
—
—
—
2.1e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:3.90%
controls:0.49%
—
—
—
—
—
—
6
8
148
1615
FVC percent change Respiratory system
69982-7 [42868471]
—
—
—
—
—
—
2.1e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:3.90%
controls:0.49%
—
—
—
—
—
—
6
8
148
1615
FEV1/FVC --post bronchodilation
69970-2 [42868459]
—
—
—
—
—
—
2.1e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:3.90%
controls:0.49%
—
—
—
—
—
—
6
8
148
1615
Physiotherapy
R4110 [2001310233]
9.5e-01
—
—
—
—
2.1e+00
8.6e-01
cases:6.04%
controls:2.42%
—
—
—
—
—
—
—
—
cases:5.20%
controls:0.67%
cases:7.14%
controls:3.14%
11
44
171
1773
—
—
—
—
9
12
164
1769
11
51
143
1572
Infiltration anesthesia
WX110 [2001310767]
1.6e-01
3.3e-01
2.0e+00
—
—
7.5e-01
3.8e-01
cases:14.29%
controls:12.38%
cases:6.59%
controls:4.84%
cases:3.30%
controls:0.44%
—
—
—
—
cases:9.25%
controls:4.60%
cases:19.48%
controls:14.17%
26
225
156
1592
12
88
170
1729
6
8
176
1809
—
—
16
82
157
1699
30
230
124
1393
clindamycin; oral, parenteral
J01FF01 [21602985]
7.6e-01
2.0e+00
—
—
—
1.1e+00
1.4e-01
cases:4.95%
controls:2.37%
cases:4.40%
controls:0.61%
—
—
—
—
—
—
cases:2.89%
controls:0.95%
cases:3.25%
controls:2.83%
9
43
173
1774
8
11
174
1806
—
—
—
5
17
168
1764
5
46
149
1577
Forced vital capacity [Volume] Respiratory system
19870-5 [3020158]
—
—
—
—
—
—
2.0e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:3.90%
controls:0.55%
—
—
—
—
—
—
6
9
148
1614
FEV1/FVC
19926-5 [3011505]
—
—
—
—
—
—
2.0e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:3.90%
controls:0.55%
—
—
—
—
—
—
6
9
148
1614
FEV1
20150-9 [3024653]
—
—
—
—
—
—
2.0e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:3.90%
controls:0.55%
—
—
—
—
—
—
6
9
148
1614
Potassium [Moles/volume] in Serum or Plasma
2823-3 [3023103]
1.5e-01
4.7e-01
1.9e+00
—
1.1e+00
4.6e-01
2.7e-01
cases:19.78%
controls:17.50%
cases:18.68%
controls:12.60%
cases:12.09%
controls:1.93%
—
—
cases:6.63%
controls:2.31%
cases:20.81%
controls:14.21%
cases:34.42%
controls:28.59%
36
318
146
1499
34
229
148
1588
22
35
160
1782
—
12
42
169
1773
36
253
137
1528
53
464
101
1159
Sodium [Moles/volume] in Serum or Plasma
2951-2 [3019550]
1.8e-01
4.8e-01
1.9e+00
—
1.1e+00
4.9e-01
3.1e-01
cases:20.33%
controls:17.50%
cases:18.68%
controls:12.44%
cases:12.09%
controls:1.93%
—
—
cases:6.63%
controls:2.31%
cases:20.81%
controls:13.87%
cases:35.06%
controls:28.28%
37
318
145
1499
34
226
148
1591
22
35
160
1782
—
12
42
169
1773
36
247
137
1534
54
459
100
1164
Office Visit
OMOP4822458 [581477]
7.8e-01
1.1e+00
—
—
—
1.1e+00
2.3e-01
cases:14.29%
controls:7.10%
cases:10.44%
controls:3.63%
—
—
—
—
—
—
cases:6.36%
controls:2.30%
cases:9.74%
controls:7.89%
26
129
156
1688
19
66
163
1751
—
—
—
11
41
162
1740
15
128
139
1495
Erythrocyte sedimentation rate [Velocity] in Red Blood Cells by Westergren method
4537-7 [3013707]
5.1e-01
8.2e-01
1.9e+00
—
—
6.4e-01
5.6e-01
cases:15.38%
controls:9.85%
cases:10.99%
controls:5.17%
cases:4.40%
controls:0.72%
—
—
—
—
cases:9.25%
controls:5.11%
cases:24.03%
controls:15.28%
28
179
154
1638
20
94
162
1723
8
13
174
1804
—
—
16
91
157
1690
37
248
117
1375
Treatment plan or consultation
WZC00 [2001310885]
8.3e-01
1.1e+00
—
—
—
1.8e+00
8.6e-01
cases:5.49%
controls:2.48%
cases:3.85%
controls:1.27%
—
—
—
—
—
—
cases:5.78%
controls:1.01%
cases:9.09%
controls:4.07%
10
45
172
1772
7
23
175
1794
—
—
—
10
18
163
1763
14
66
140
1557
Blood type and Crossmatch panel - Blood
34531-4 [3044640]
5.5e-01
1.3e+00
—
—
—
1.8e+00
7.6e-01
cases:6.04%
controls:3.58%
cases:4.95%
controls:1.38%
—
—
—
—
—
—
cases:7.51%
controls:1.35%
cases:8.44%
controls:4.13%
11
65
171
1752
9
25
173
1792
—
—
—
13
24
160
1757
13
67
141
1556
More than one and less than three hours
ZXE10 [2001311401]
4.7e-01
—
—
1.0e+50
—
1.7e+00
6.6e-01
cases:6.04%
controls:3.85%
—
—
—
—
cases:2.75%
controls:0.00%
—
—
cases:5.78%
controls:1.07%
cases:6.49%
controls:3.45%
11
70
171
1747
—
—
5
0
177
1817
—
10
19
163
1762
10
56
144
1567
Skin texture symptom/complaint
S21 [2002000986]
1.7e+00
—
—
—
—
—
1.7e+00
cases:3.30%
controls:0.61%
—
—
—
—
—
—
—
—
—
—
cases:5.84%
controls:1.11%
6
11
176
1806
—
—
—
—
—
9
18
145
1605
Urgent procedure
ZXD05 [2001311386]
5.7e-01
1.7e+00
—
—
—
—
—
cases:6.04%
controls:3.52%
cases:4.40%
controls:0.83%
—
—
—
—
—
—
—
—
—
—
11
64
171
1753
8
15
174
1802
—
—
—
—
—
Phosphate [Moles/volume] in Serum or Plasma
14879-1 [3003458]
1.7e+00
1.6e+00
—
—
—
1.7e+00
1.2e+00
cases:4.95%
controls:0.94%
cases:3.30%
controls:0.72%
—
—
—
—
—
—
cases:2.89%
controls:0.56%
cases:6.49%
controls:1.97%
9
17
173
1800
6
13
176
1804
—
—
—
5
10
168
1771
10
32
144
1591
Prothrombin time (PT) actual/Normal
5894-1 [3033658]
6.6e-01
1.3e+00
—
—
—
1.7e+00
7.3e-01
cases:4.40%
controls:2.31%
cases:4.40%
controls:1.21%
—
—
—
—
—
—
cases:5.20%
controls:1.01%
cases:5.84%
controls:2.90%
8
42
174
1775
8
22
174
1795
—
—
—
9
18
164
1763
9
47
145
1576
Medical Oncology
90 [38004507]
8.5e-01
1.1e+00
—
—
1.2e+00
1.6e+00
1.0e+00
cases:6.59%
controls:2.92%
cases:5.49%
controls:1.93%
—
—
—
—
cases:2.76%
controls:0.83%
cases:10.40%
controls:2.19%
cases:9.09%
controls:3.45%
12
53
170
1764
10
35
172
1782
—
—
5
15
176
1800
18
39
155
1742
14
56
140
1567
Hemoglobin [Mass/volume] in Blood
718-7 [3000963]
1.9e-01
4.7e-01
1.5e+00
—
9.0e-01
3.3e-01
2.4e-01
cases:24.18%
controls:20.86%
cases:24.18%
controls:16.68%
cases:13.74%
controls:3.36%
—
—
cases:9.94%
controls:4.30%
cases:24.86%
controls:19.15%
cases:40.91%
controls:35.18%
44
379
138
1438
44
303
138
1514
25
61
157
1756
—
18
78
163
1737
43
341
130
1440
63
571
91
1052
Erythrocytes [#/volume] in Blood
26453-1 [3026361]
1.7e-01
4.7e-01
1.5e+00
—
9.0e-01
3.4e-01
2.4e-01
cases:23.63%
controls:20.69%
cases:24.18%
controls:16.68%
cases:13.74%
controls:3.36%
—
—
cases:9.94%
controls:4.30%
cases:24.86%
controls:19.09%
cases:40.91%
controls:35.18%
43
376
139
1441
44
303
138
1514
25
61
157
1756
—
18
78
163
1737
43
340
130
1441
63
571
91
1052
Platelets [#/volume] in Blood
26515-7 [3007461]
2.0e-01
4.7e-01
1.5e+00
—
9.1e-01
3.4e-01
2.5e-01
cases:24.18%
controls:20.64%
cases:24.18%
controls:16.68%
cases:13.74%
controls:3.36%
—
—
cases:9.94%
controls:4.24%
cases:24.86%
controls:19.03%
cases:40.91%
controls:35.00%
44
375
138
1442
44
303
138
1514
25
61
157
1756
—
18
77
163
1738
43
339
130
1442
63
568
91
1055
MCV [Entitic mean volume] in Red Blood Cells
30428-7 [3024731]
2.0e-01
4.7e-01
1.5e+00
—
9.0e-01
3.4e-01
2.4e-01
cases:24.18%
controls:20.69%
cases:24.18%
controls:16.68%
cases:13.74%
controls:3.36%
—
—
cases:9.94%
controls:4.30%
cases:24.86%
controls:19.09%
cases:40.91%
controls:35.18%
44
376
138
1441
44
303
138
1514
25
61
157
1756
—
18
78
163
1737
43
340
130
1441
63
571
91
1052
MCH [Entitic mass]
28539-5 [3035941]
1.7e-01
4.7e-01
1.5e+00
—
9.0e-01
3.5e-01
2.5e-01
cases:23.63%
controls:20.69%
cases:24.18%
controls:16.68%
cases:13.74%
controls:3.36%
—
—
cases:9.94%
controls:4.30%
cases:24.86%
controls:18.98%
cases:40.91%
controls:35.12%
43
376
139
1441
44
303
138
1514
25
61
157
1756
—
18
78
163
1737
43
338
130
1443
63
570
91
1053
Hematocrit [Volume Fraction] of Blood by calculation
20570-8 [3009542]
2.0e-01
4.7e-01
1.5e+00
—
9.0e-01
3.4e-01
2.5e-01
cases:24.18%
controls:20.69%
cases:24.18%
controls:16.68%
cases:13.74%
controls:3.36%
—
—
cases:9.94%
controls:4.30%
cases:24.86%
controls:19.09%
cases:40.91%
controls:35.12%
44
376
138
1441
44
303
138
1514
25
61
157
1756
—
18
78
163
1737
43
340
130
1441
63
570
91
1053
ciprofloxacin; oral, parenteral
J01MA02 [21603009]
2.2e-01
1.3e+00
—
—
—
1.5e+00
3.6e-01
cases:6.59%
controls:5.34%
cases:4.95%
controls:1.43%
—
—
—
—
—
—
cases:6.36%
controls:1.46%
cases:7.79%
controls:5.55%
12
97
170
1720
9
26
173
1791
—
—
—
11
26
162
1755
12
90
142
1533
Leukocytes [#/volume] in Blood
26464-8 [3010813]
2.0e-01
4.6e-01
1.5e+00
—
9.0e-01
3.4e-01
2.5e-01
cases:24.18%
controls:20.69%
cases:24.18%
controls:16.73%
cases:13.74%
controls:3.41%
—
—
cases:9.94%
controls:4.30%
cases:24.86%
controls:19.09%
cases:40.91%
controls:35.06%
44
376
138
1441
44
304
138
1513
25
62
157
1755
—
18
78
163
1737
43
340
130
1441
63
569
91
1054
MCHC [Entitic Mass/volume] in Red Blood Cells
28540-3 [3003338]
-2.0e-03
1.4e-01
1.5e+00
—
7.2e-01
1.7e-01
1.8e-01
cases:15.93%
controls:15.96%
cases:13.19%
controls:11.67%
cases:9.34%
controls:2.31%
—
—
cases:5.52%
controls:2.75%
cases:15.03%
controls:12.97%
cases:29.87%
controls:26.31%
29
290
153
1527
24
212
158
1605
17
42
165
1775
—
10
50
171
1765
26
231
147
1550
46
427
108
1196
zolpidem; oral
N05CF02 [21604655]
6.6e-01
8.1e-01
—
—
—
1.5e+00
4.5e-01
cases:5.49%
controls:2.92%
cases:3.30%
controls:1.49%
—
—
—
—
—
—
cases:5.78%
controls:1.40%
cases:5.19%
controls:3.39%
10
53
172
1764
6
27
176
1790
—
—
—
10
25
163
1756
8
55
146
1568
Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma
1742-6 [3006923]
3.1e-01
4.0e-01
1.5e+00
—
7.0e-01
2.8e-01
2.0e-01
cases:22.53%
controls:17.56%
cases:18.13%
controls:12.88%
cases:8.79%
controls:2.20%
—
—
cases:4.97%
controls:2.53%
cases:19.08%
controls:15.10%
cases:34.42%
controls:30.01%
41
319
141
1498
33
234
149
1583
16
40
166
1777
—
9
46
172
1769
33
269
140
1512
53
487
101
1136
Holo-transcobalamin II [Moles/volume] in Serum
72160-5 [43054903]
6.2e-01
5.9e-01
—
—
—
1.4e+00
2.6e-01
cases:7.14%
controls:3.96%
cases:4.40%
controls:2.48%
—
—
—
—
—
—
cases:6.36%
controls:1.68%
cases:9.09%
controls:7.15%
13
72
169
1745
8
45
174
1772
—
—
—
11
30
162
1751
14
116
140
1507
Calcium.ionized [Moles/volume] in Serum or Plasma
1995-0 [3021347]
5.4e-01
1.0e+00
—
—
—
1.3e+00
6.9e-01
cases:7.69%
controls:4.62%
cases:6.59%
controls:2.42%
—
—
—
—
—
—
cases:6.94%
controls:1.91%
cases:12.34%
controls:6.59%
14
84
168
1733
12
44
170
1773
—
—
—
12
34
161
1747
19
107
135
1516
Other specified special examinations
Z01.8 [45581003]
1.1e+00
—
—
—
—
—
1.3e+00
cases:4.95%
controls:1.76%
—
—
—
—
—
—
—
—
—
—
cases:9.74%
controls:2.83%
9
32
173
1785
—
—
—
—
—
15
46
139
1577
sulfadiazine and trimethoprim
J01EE02 [21602962]
1.3e+00
—
—
—
—
—
6.3e-01
cases:9.89%
controls:3.03%
—
—
—
—
—
—
—
—
—
—
cases:4.55%
controls:2.46%
18
55
164
1762
—
—
—
—
—
7
40
147
1583
Erythrocyte [DistWidth] in Red Blood Cells
30385-9 [3002385]
-7.2e-02
1.7e-01
1.2e+00
—
5.9e-01
2.3e-01
1.6e-01
cases:13.19%
controls:14.03%
cases:13.19%
controls:11.39%
cases:7.69%
controls:2.37%
—
—
cases:4.97%
controls:2.81%
cases:14.45%
controls:11.79%
cases:25.32%
controls:22.43%
24
255
158
1562
24
207
158
1610
14
43
168
1774
—
9
51
172
1764
25
210
148
1571
39
364
115
1259
Gastroenterology
10 [38004455]
8.6e-01
1.1e+00
—
—
—
8.7e-01
1.2e+00
cases:7.69%
controls:3.41%
cases:4.95%
controls:1.65%
—
—
—
—
—
—
cases:5.20%
controls:2.25%
cases:16.23%
controls:5.36%
14
62
168
1755
9
30
173
1787
—
—
—
9
40
164
1741
25
87
129
1536
Calcium.ionized [Moles/volume] adjusted to pH 7.4 in Serum or Plasma
19072-8 [3016431]
3.1e-01
8.7e-01
—
—
—
1.2e+00
5.6e-01
cases:7.14%
controls:5.34%
cases:6.59%
controls:2.86%
—
—
—
—
—
—
cases:7.51%
controls:2.36%
cases:13.64%
controls:8.26%
13
97
169
1720
12
52
170
1765
—
—
—
13
42
160
1739
21
134
133
1489
trimethoprim; oral, parenteral
J01EA01 [21602931]
7.1e-02
1.2e+00
—
—
—
8.7e-01
-5.3e-01
cases:4.95%
controls:4.62%
cases:7.69%
controls:2.42%
—
—
—
—
—
—
cases:5.20%
controls:2.25%
cases:3.90%
controls:6.47%
9
84
173
1733
14
44
168
1773
—
—
—
9
40
164
1741
6
105
148
1518
Ferritin [Mass/volume] in Serum or Plasma
2276-4 [3001122]
5.3e-01
7.3e-01
—
—
—
1.1e+00
3.5e-01
cases:8.79%
controls:5.39%
cases:7.14%
controls:3.58%
—
—
—
—
—
—
cases:8.09%
controls:2.81%
cases:12.34%
controls:9.06%
16
98
166
1719
13
65
169
1752
—
—
—
14
50
159
1731
19
147
135
1476
Bacteria [#/volume] in Urine by Automated count
51480-2 [3031040]
3.4e-01
1.1e+00
—
—
—
3.8e-01
-2.1e-01
cases:11.54%
controls:8.53%
cases:11.54%
controls:4.18%
—
—
—
—
—
—
cases:6.94%
controls:4.83%
cases:11.04%
controls:13.31%
21
155
161
1662
21
76
161
1741
—
—
—
12
86
161
1695
17
216
137
1407
Emergency Medicine
93 [38004510]
4.1e-01
1.1e+00
—
—
—
2.5e-01
3.6e-01
cases:11.54%
controls:7.98%
cases:10.44%
controls:3.85%
—
—
—
—
—
—
cases:5.78%
controls:4.55%
cases:16.88%
controls:12.45%
21
145
161
1672
19
70
163
1747
—
—
—
10
81
163
1700
26
202
128
1421
Calcium [Moles/volume] in Serum or Plasma
2000-8 [3015377]
1.0e+00
9.2e-01
2.1e+00
—
—
8.9e-01
4.4e-01
cases:8.24%
controls:3.14%
cases:4.95%
controls:2.04%
cases:2.75%
controls:0.33%
—
—
—
—
cases:3.47%
controls:1.46%
cases:7.79%
controls:5.18%
15
57
167
1760
9
37
173
1780
5
6
177
1811
—
—
6
26
167
1755
12
84
142
1539
mometasone; nasal
R01AD09 [21605051]
5.6e-01
8.3e-01
—
—
—
4.5e-02
8.9e-01
cases:13.74%
controls:8.31%
cases:7.14%
controls:3.25%
—
—
—
—
—
—
cases:4.05%
controls:3.87%
cases:18.83%
controls:8.69%
25
151
157
1666
13
59
169
1758
—
—
—
7
69
166
1712
29
141
125
1482
cetirizine; oral
R06AE07 [21603497]
3.0e-01
-1.6e-02
—
—
—
6.7e-01
8.0e-01
cases:10.44%
controls:7.93%
cases:3.85%
controls:3.91%
—
—
—
—
—
—
cases:6.36%
controls:3.37%
cases:16.23%
controls:8.01%
19
144
163
1673
7
71
175
1746
—
—
—
11
60
162
1721
25
130
129
1493
Neutrophils [#/volume] in Blood by Automated count
751-8 [3013650]
4.4e-01
8.8e-01
1.2e+00
—
—
8.0e-01
7.7e-01
cases:10.99%
controls:7.37%
cases:9.89%
controls:4.35%
cases:3.85%
controls:1.21%
—
—
—
—
cases:8.67%
controls:4.10%
cases:18.83%
controls:9.67%
20
134
162
1683
18
79
164
1738
7
22
175
1795
—
—
15
73
158
1708
29
157
125
1466
combinations of corticosteroids
D07AB30 [21602118]
-1.0e-01
7.6e-01
—
—
—
-1.4e-01
6.2e-01
cases:9.34%
controls:10.24%
cases:6.59%
controls:3.19%
—
—
—
—
—
—
cases:2.89%
controls:3.31%
cases:16.23%
controls:9.43%
17
186
165
1631
12
58
170
1759
—
—
—
5
59
168
1722
25
153
129
1470
Other chronic pain
R52.2 [45568139]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.33%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.31%
0
6
182
1811
—
—
—
—
—
0
5
154
1618
Simple examination of mouth
SAA01 [2001310274]
2.8e-01
3.4e-02
—
—
—
1.0e-01
4.7e-01
cases:17.58%
controls:13.87%
cases:6.59%
controls:6.38%
—
—
—
—
—
—
cases:6.36%
controls:5.78%
cases:26.62%
controls:18.55%
32
252
150
1565
12
116
170
1701
—
—
—
11
103
162
1678
41
301
113
1322
Cholesterol in HDL [Moles/volume] in Serum or Plasma
14646-4 [3023602]
2.9e-01
1.2e-02
—
—
-1.0e+50
4.4e-01
-1.4e-01
cases:18.68%
controls:14.64%
cases:8.79%
controls:8.70%
—
—
—
—
cases:0.00%
controls:1.21%
cases:14.45%
controls:9.77%
cases:23.38%
controls:26.06%
34
266
148
1551
16
158
166
1659
—
—
0
22
181
1793
25
174
148
1607
36
423
118
1200
Cervicobrachial syndrome
M53.1 [45567577]
—
—
—
—
—
-1.0e+50
-1.0e+50
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.34%
cases:0.00%
controls:1.60%
—
—
—
—
—
0
6
173
1775
0
26
154
1597
Verruca simplex
B07.9 [2000500357]
-1.0e+50
—
—
—
—
-1.0e+50
—
cases:0.00%
controls:0.33%
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.34%
—
—
0
6
182
1811
—
—
—
—
0
6
173
1775
—
Fractional scraping
8113 [2000101291]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.28%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
182
1812
—
—
—
—
—
—
Neck artery ultrasound examination with Doppler method
PA6DE [2001308705]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.33%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.31%
0
6
182
1811
—
—
—
—
—
0
5
154
1618
Polyneuropathy, unspecified
G62.9 [45566898]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.39%
—
—
—
—
—
—
—
—
—
—
—
—
0
7
182
1810
—
—
—
—
—
—
diclofenac, combinations; oral
M01AB55 [21603959]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.28%
—
—
—
—
—
—
—
0
5
173
1776
—
tretinoin; ointment
D10AD01 [21602293]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.28%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
182
1812
—
—
—
—
—
—
Labour and delivery complicated by fetal heart rate anomaly
O68.0 [45548818]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.28%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
182
1812
—
—
—
—
—
—
Other minor procedure in surgery of ear, nose and larynx
TDW99 [2001301879]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.33%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
182
1811
—
—
—
—
—
—
Combined first trimester screening
MA3AE [2001306839]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.44%
—
—
—
—
—
—
—
—
—
—
—
—
0
8
182
1809
—
—
—
—
—
—
tibolone; oral
G03CX01 [21602536]
1.4e+00
1.6e+00
—
—
—
—
—
cases:3.30%
controls:0.83%
cases:2.75%
controls:0.55%
—
—
—
—
—
—
—
—
—
—
6
15
176
1802
5
10
177
1807
—
—
—
—
—
estradiol; nasal, oral, parenteral, rectal, transdermal, vaginal
G03CA03 [21602517]
1.5e-03
2.6e-01
3.7e-01
—
6.4e-01
4.3e-01
3.6e-01
cases:19.23%
controls:19.21%
cases:18.13%
controls:14.64%
cases:4.95%
controls:3.47%
—
—
cases:6.08%
controls:3.31%
cases:21.97%
controls:15.50%
cases:30.52%
controls:23.48%
35
349
147
1468
33
266
149
1551
9
63
173
1754
—
11
60
170
1755
38
276
135
1505
47
381
107
1242
Achilles tendinitis
M76.6 [45596682]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.37%
—
—
—
—
—
—
0
6
154
1617
Total mastectomy
HAC20 [2001303934]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.39%
—
—
—
—
—
—
—
—
—
—
—
—
0
7
182
1810
—
—
—
—
—
—
Dislocation, sprain and strain of joints and ligaments of knee
S83 [45755848]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.37%
—
—
—
—
—
—
0
6
154
1617
Conjunctivitis
H10 [45581570]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.28%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.37%
0
5
182
1812
—
—
—
—
—
0
6
154
1617
Palmar fascial fibromatosis [Dupuytren]
M72.0 [45543681]
-1.0e+50
—
—
—
—
-1.0e+50
-1.0e+50
cases:0.00%
controls:0.50%
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.28%
cases:0.00%
controls:0.31%
0
9
182
1808
—
—
—
—
0
5
173
1776
0
5
154
1618
Gastrointestinal bacterial pathogens panel - Stool by NAA with probe detection
92695-6 [37019628]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.55%
—
—
—
—
—
—
0
9
154
1614
Bicarbonate [Moles/volume] in Venous blood
14627-4 [3027273]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.28%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
182
1812
—
—
—
—
—
—
Acute cystitis
N30.0 [45601724]
1.2e+00
—
—
—
—
—
—
cases:2.75%
controls:0.83%
—
—
—
—
—
—
—
—
—
—
—
—
5
15
177
1802
—
—
—
—
—
—
levothyroxine sodium; oral, parenteral
H03AA01 [21602754]
7.1e-01
6.2e-01
2.0e-01
—
—
5.7e-01
4.2e-01
cases:15.38%
controls:8.20%
cases:14.84%
controls:8.59%
cases:2.75%
controls:2.26%
—
—
—
—
cases:15.03%
controls:9.10%
cases:16.23%
controls:11.28%
28
149
154
1668
27
156
155
1661
5
41
177
1776
—
—
26
162
147
1619
25
183
129
1440
Health check-up of pregnant person
SPAT1379 [2001700479]
—
-1.0e+50
-1.0e+50
—
—
—
-1.0e+50
—
—
cases:0.00%
controls:0.66%
cases:0.00%
controls:0.28%
—
—
—
—
—
—
cases:0.00%
controls:0.86%
—
0
12
182
1805
0
5
182
1812
—
—
—
0
14
154
1609
COVID-19, virus not identified
U07.2 [45756094]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.85%
—
—
—
—
—
—
0
30
154
1593
Abdominal aortic aneurysm, without mention of rupture
I71.4 [45572130]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.44%
—
—
—
—
—
—
—
—
—
—
—
—
0
8
182
1809
—
—
—
—
—
—
pravastatin; oral
C10AA03 [21601858]
—
-1.0e+50
-1.0e+50
—
—
-1.0e+50
—
—
—
cases:0.00%
controls:0.55%
cases:0.00%
controls:0.28%
—
—
—
—
cases:0.00%
controls:0.56%
—
—
—
0
10
182
1807
0
5
182
1812
—
—
0
10
173
1771
—
olanzapine; oral, parenteral
N05AH03 [21604543]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.68%
—
—
—
—
—
—
0
11
154
1612
Fetal Trisomy 21 risk [Likelihood] Based on maternal age
49090-4 [3049207]
-1.0e+50
-1.0e+50
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.77%
cases:0.00%
controls:0.28%
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.31%
0
14
182
1803
0
5
182
1812
—
—
—
—
0
5
154
1618
Basic examination of mouth
SAA02 [2001310275]
1.2e-01
7.5e-01
—
—
-1.0e+50
-2.7e-01
3.2e-01
cases:13.19%
controls:11.83%
cases:7.14%
controls:3.52%
—
—
—
—
cases:0.00%
controls:0.33%
cases:3.47%
controls:4.49%
cases:20.13%
controls:15.53%
24
215
158
1602
13
64
169
1753
—
—
0
6
181
1809
6
80
167
1701
31
252
123
1371
Radiotherapy after total ablation of mammary gland
HA013 [2001303966]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.28%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
182
1812
—
—
—
—
—
—
Observation for suspected disease or condition, unspecified
Z03.9 [45552062]
1.2e+00
—
—
—
—
—
6.5e-01
cases:3.85%
controls:1.16%
—
—
—
—
—
—
—
—
—
—
cases:3.25%
controls:1.73%
7
21
175
1796
—
—
—
—
—
5
28
149
1595
Tooth X-ray additional picture
EB1CA [2001301909]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.44%
—
—
—
—
—
—
—
—
—
—
—
—
0
8
182
1809
—
—
—
—
—
—
formoterol, glycopyrronium bromide and budesonide
R03AL11 [715850]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:1.32%
—
—
—
—
—
—
—
—
—
—
—
—
0
24
182
1793
—
—
—
—
—
—
IgA [Mass/volume] in Serum or Plasma
2458-8 [3007164]
1.1e+00
—
—
—
—
—
7.0e-01
cases:4.95%
controls:1.65%
—
—
—
—
—
—
—
—
—
—
cases:5.19%
controls:2.65%
9
30
173
1787
—
—
—
—
—
8
43
146
1580
Uroflowmetry
44856007 [4261340]
1.0e+00
—
—
—
—
—
—
cases:2.75%
controls:0.99%
—
—
—
—
—
—
—
—
—
—
—
—
5
18
177
1799
—
—
—
—
—
—
Rectal ultrasound examination of prostate
KE1BE [2001306106]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.61%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.68%
0
11
182
1806
—
—
—
—
—
0
11
154
1612
tenoxicam; oral, parenteral, rectal
M01AC02 [21603962]
-1.0e+50
-1.0e+50
—
—
—
—
—
cases:0.00%
controls:0.33%
cases:0.00%
controls:0.33%
—
—
—
—
—
—
—
—
—
—
0
6
182
1811
0
6
182
1811
—
—
—
—
—
dexrabeprazole
A02BC07 [45893509]
—
-1.0e+50
—
—
—
-1.0e+50
—
—
—
cases:0.00%
controls:0.39%
—
—
—
—
—
—
cases:0.00%
controls:0.51%
—
—
—
0
7
182
1810
—
—
—
0
9
173
1772
—
Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma
1920-8 [3013721]
5.8e-01
3.9e-01
—
—
-1.0e+50
—
6.0e-01
cases:6.04%
controls:3.47%
cases:2.75%
controls:1.87%
—
—
—
—
cases:0.00%
controls:0.28%
—
—
cases:9.74%
controls:5.61%
11
63
171
1754
5
34
177
1783
—
—
0
5
181
1810
—
15
91
139
1532
ursodeoxycholic acid; oral
A05AA02 [21600513]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.37%
—
—
—
—
—
—
0
6
154
1617
amlodipine; oral
C08CA01 [21601747]
5.8e-01
6.1e-01
—
—
—
5.0e-01
-4.7e-02
cases:9.89%
controls:5.78%
cases:9.34%
controls:5.28%
—
—
—
—
—
—
cases:8.67%
controls:5.45%
cases:8.44%
controls:8.81%
18
105
164
1712
17
96
165
1721
—
—
—
15
97
158
1684
13
143
141
1480
Cramp and spasm
R25.2 [45592414]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.31%
—
—
—
—
—
—
0
5
154
1618
Remote monitoring CPAP
WX780 [2001310837]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.49%
—
—
—
—
—
—
0
8
154
1615
Dyspnoea
R06.0 [45558449]
5.2e-01
—
—
—
—
—
4.0e-01
cases:3.30%
controls:1.98%
—
—
—
—
—
—
—
—
—
—
cases:4.55%
controls:3.08%
6
36
176
1781
—
—
—
—
—
7
50
147
1573
acetylsalicylic acid, combinations excl. psycholeptics
N02BA51 [21604320]
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.39%
—
—
—
—
—
—
—
—
0
7
181
1808
—
—
enoxaparin; parenteral
B01AB05 [21600976]
6.1e-01
1.3e+00
—
—
—
7.4e-01
2.6e-01
cases:4.95%
controls:2.75%
cases:3.85%
controls:1.05%
—
—
—
—
—
—
cases:2.89%
controls:1.40%
cases:5.19%
controls:4.07%
9
50
173
1767
7
19
175
1798
—
—
—
5
25
168
1756
8
66
146
1557
Spirometry study
18759-1 [3000492]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.45%
—
—
—
—
—
—
—
0
8
173
1773
—
Physiotherapist
Z3226 [2001311560]
6.7e-01
—
—
—
—
—
7.6e-01
cases:2.75%
controls:1.43%
—
—
—
—
—
—
—
—
—
—
cases:3.25%
controls:1.54%
5
26
177
1791
—
—
—
—
—
5
25
149
1598
Cannabinoids [Presence] in Urine
3427-2 [3028300]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.44%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.43%
0
8
182
1809
—
—
—
—
—
0
7
154
1616
lercanidipine; oral
C08CA13 [21601759]
1.0e+00
7.5e-01
—
—
—
7.8e-01
4.7e-01
cases:4.95%
controls:1.82%
cases:2.75%
controls:1.32%
—
—
—
—
—
—
cases:2.89%
controls:1.35%
cases:3.90%
controls:2.46%
9
33
173
1784
5
24
177
1793
—
—
—
5
24
168
1757
6
40
148
1583
Cardiac arrhythmia, unspecified
I49.9 [45581778]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.44%
—
—
—
—
—
—
—
—
—
—
—
0
8
182
1809
—
—
—
—
—
nilvadipine; oral
C08CA10 [21601756]
-1.0e+50
-1.0e+50
—
—
—
-1.0e+50
-1.0e+50
cases:0.00%
controls:0.33%
cases:0.00%
controls:0.28%
—
—
—
—
—
—
cases:0.00%
controls:0.28%
cases:0.00%
controls:0.31%
0
6
182
1811
0
5
182
1812
—
—
—
0
5
173
1776
0
5
154
1618
Zoster without complication
B02.9 [45581143]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.43%
—
—
—
—
—
—
0
7
154
1616
Obesity, unspecified
E66.9 [45576460]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.39%
—
—
—
—
—
—
—
—
—
—
—
—
0
7
182
1810
—
—
—
—
—
—
SMOKING - SMOKE2: yes - SMOKE3: current - SMOKE5: current
SMOKING-1-1-1 [2002330115]
-1.0e+50
-1.0e+50
—
—
—
—
—
cases:0.00%
controls:1.43%
cases:0.00%
controls:0.44%
—
—
—
—
—
—
—
—
—
—
0
26
182
1791
0
8
182
1809
—
—
—
—
—
Blepharitis
H01.0 [45533180]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.62%
—
—
—
—
—
—
0
10
154
1613
diclofenac; oral, parenteral, rectal
M01AB05 [21603945]
1.0e-02
2.5e-01
1.7e+00
—
-1.0e+50
-2.9e-01
3.6e-01
cases:16.48%
controls:16.35%
cases:6.59%
controls:5.23%
cases:2.75%
controls:0.50%
—
—
cases:0.00%
controls:0.72%
cases:4.05%
controls:5.33%
cases:20.13%
controls:14.91%
30
297
152
1520
12
95
170
1722
5
9
177
1808
—
0
13
181
1802
7
95
166
1686
31
242
123
1381
Spinalanesthesia
WX320 [2001310799]
—
—
—
—
—
—
6.3e-01
—
—
—
—
—
—
—
—
—
—
—
—
cases:4.55%
controls:2.46%
—
—
—
—
—
—
7
40
147
1583
Pulpit UNS
K04.09 [2000502704]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.28%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
182
1812
—
—
—
—
—
—
Other psoriatic arthropathies
M07.3*L40.5 [2000503010]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.31%
—
—
—
—
—
—
0
5
154
1618
Sprain and strain of shoulder joint
S43.4 [45607418]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.50%
—
—
—
—
—
—
—
—
—
—
—
—
0
9
182
1808
—
—
—
—
—
—
fusidic acid
S01AA13 [21603564]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.74%
—
—
—
—
—
—
0
12
154
1611
25-Hydroxyvitamin D3+25-Hydroxyvitamin D2 [Moles/volume] in Serum or Plasma
68438-1 [40771025]
5.9e-01
5.5e-01
—
—
—
9.6e-01
5.1e-01
cases:7.69%
controls:4.40%
cases:5.49%
controls:3.25%
—
—
—
—
—
—
cases:5.78%
controls:2.30%
cases:12.34%
controls:7.76%
14
80
168
1737
10
59
172
1758
—
—
—
10
41
163
1740
19
126
135
1497
EKG study
11524-6 [3013512]
5.1e-01
1.1e+00
—
—
—
—
2.2e-01
cases:4.95%
controls:3.03%
cases:3.85%
controls:1.27%
—
—
—
—
—
—
—
—
cases:7.14%
controls:5.79%
9
55
173
1762
7
23
175
1794
—
—
—
—
11
94
143
1529
Physical Medicine And Rehabilitation
25 [38004468]
2.8e-01
9.8e-01
—
—
—
9.4e-01
6.4e-01
cases:6.59%
controls:5.06%
cases:6.04%
controls:2.37%
—
—
—
—
—
—
cases:4.62%
controls:1.85%
cases:12.34%
controls:6.90%
12
92
170
1725
11
43
171
1774
—
—
—
8
33
165
1748
19
112
135
1511
amitriptyline; oral, parenteral
N06AA09 [21604696]
—
—
-1.0e+50
—
—
—
3.0e-01
—
—
—
—
cases:0.00%
controls:0.28%
—
—
—
—
—
—
cases:5.19%
controls:3.88%
—
—
0
5
182
1812
—
—
—
8
63
146
1560
Type 2 diabetes mellitus
E11 [45571656]
3.7e-01
—
—
—
—
8.2e-01
-3.1e-02
cases:5.49%
controls:3.85%
—
—
—
—
—
—
—
—
cases:2.89%
controls:1.29%
cases:4.55%
controls:4.68%
10
70
172
1747
—
—
—
—
5
23
168
1758
7
76
147
1547
Hematology
82 [38004501]
—
—
—
—
—
—
1.2e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:3.25%
controls:1.05%
—
—
—
—
—
—
5
17
149
1606
Basal cell carcinoma, NOS, of skin of other and unspecified parts of face
8090/3-C44.3 [44499724]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.28%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
182
1812
—
—
—
—
—
—
Rheumatism, unspecified
M79.0 [45567658]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.37%
—
—
—
—
—
—
0
6
154
1617
Type 1 diabetes mellitus, Without complications
E10.9 [45581351]
—
—
-1.0e+50
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.28%
—
—
—
—
—
—
—
—
—
—
0
5
182
1812
—
—
—
—
Lumbar epidural anesthesia
WX306 [2001310796]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.88%
—
—
—
—
—
—
—
—
—
—
—
—
0
16
182
1801
—
—
—
—
—
—
Assessment of need for oral health care, extensive
SAD02 [2001310288]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.39%
—
—
—
—
—
—
—
—
—
—
—
—
0
7
182
1810
—
—
—
—
—
—
hydrocortisone buteprate
D07AB11 [21602115]
-6.3e-02
—
—
—
—
3.7e-01
2.5e-01
cases:6.59%
controls:6.99%
—
—
—
—
—
—
—
—
cases:2.89%
controls:2.02%
cases:8.44%
controls:6.72%
12
127
170
1690
—
—
—
—
5
36
168
1745
13
109
141
1514
Acceptance of acknowledgement of paternity of child born outside of marriage before the birth of the child at the maternity clinic. Paternity Act, Section 16.
SPAT1399 [2001700499]
-1.0e+50
-1.0e+50
—
—
—
—
—
cases:0.00%
controls:0.39%
cases:0.00%
controls:0.28%
—
—
—
—
—
—
—
—
—
—
0
7
182
1810
0
5
182
1812
—
—
—
—
—
nepafenac
S01BC10 [21603648]
-1.0e+50
—
—
—
—
-1.0e+50
-1.0e+50
cases:0.00%
controls:0.33%
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.39%
cases:0.00%
controls:1.05%
0
6
182
1811
—
—
—
—
0
7
173
1774
0
17
154
1606
benzathine phenoxymethylpenicillin; oral
J01CE10 [21602850]
-1.1e-01
1.1e+00
—
—
—
—
2.6e-01
cases:9.89%
controls:10.90%
cases:7.14%
controls:2.53%
—
—
—
—
—
—
—
—
cases:12.99%
controls:10.29%
18
198
164
1619
13
46
169
1771
—
—
—
—
20
167
134
1456
Adaptation disorder with mixed anxiety and depression
F43.22 [2000502003]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.28%
—
—
—
—
—
—
—
0
5
173
1776
—
Choriogonadotropin.intact+Beta subunit [Mass/volume] in Serum or Plasma
93769-8 [1002102]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.39%
—
—
—
—
—
—
—
—
—
—
—
—
0
7
182
1810
—
—
—
—
—
—
Unspecified haematuria
R31 [45553726]
—
—
—
—
—
-1.0e+50
-1.0e+50
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.28%
cases:0.00%
controls:0.86%
—
—
—
—
—
0
5
173
1776
0
14
154
1609
flecainide; oral, parenteral
C01BC04 [21600266]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.31%
—
—
—
—
—
—
0
5
154
1618
oseltamivir; oral
J05AH02 [21603179]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.50%
—
—
—
—
—
—
—
—
—
—
—
—
0
9
182
1808
—
—
—
—
—
—
Monocytes/Leukocytes in Blood
26485-3 [3019069]
2.0e-01
9.1e-01
—
—
—
7.9e-01
4.9e-01
cases:7.14%
controls:5.94%
cases:7.69%
controls:3.25%
—
—
—
—
—
—
cases:6.94%
controls:3.26%
cases:12.34%
controls:7.95%
13
108
169
1709
14
59
168
1758
—
—
—
12
58
161
1723
19
129
135
1494
Spondylolisthesis
M43.1 [45606219]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.28%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
182
1812
—
—
—
—
—
—
nystatin; vaginal
G01AA01 [21602363]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.72%
—
—
—
—
—
—
—
—
—
—
—
—
0
13
182
1804
—
—
—
—
—
—
codeine; oral
R05DA04 [21603399]
—
—
—
—
—
—
6.8e-01
—
—
—
—
—
—
—
—
—
—
—
—
cases:5.19%
controls:2.71%
—
—
—
—
—
—
8
44
146
1579
Assessment of need for services (elderly/care support)
SPAT1217 [2001700318]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.33%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
182
1811
—
—
—
—
—
—
epinephrine; parenteral
C01CA24 [21600303]
—
—
—
—
—
—
1.3e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:3.90%
controls:1.05%
—
—
—
—
—
—
6
17
148
1606
Aortic (valve) stenosis with insufficiency
I35.2 [45562346]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.37%
—
—
—
—
—
—
0
6
154
1617
Other internal derangements of knee
M23.8 [45548371]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.28%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
182
1812
—
—
—
—
—
—
Visual field testing with Humphrey automated perimetry
CS434 [2001301476]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.39%
—
—
—
—
—
—
—
—
—
—
—
—
0
7
182
1810
—
—
—
—
—
—
Suppurative and unspecified otitis media
H66 [45538332]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.28%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
182
1812
—
—
—
—
—
—
Electrocardiogram with exercise test
46136006 [4261794]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.28%
—
—
—
—
—
—
—
0
5
173
1776
—
Gynaecological examination (general)(routine)
Z01.4 [45542395]
—
—
—
—
—
1.3e+00
—
—
—
—
—
—
—
—
—
—
—
cases:2.89%
controls:0.79%
—
—
—
—
—
—
—
5
14
168
1767
—
Nuclear Ab [Titer] in Serum
29953-7 [3037522]
1.2e+00
—
—
—
—
—
—
cases:4.95%
controls:1.49%
—
—
—
—
—
—
—
—
—
—
—
—
9
27
173
1790
—
—
—
—
—
—
lovastatin; oral
C10AA02 [21601857]
—
—
-1.0e+50
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.28%
—
—
—
—
—
—
—
—
—
—
0
5
182
1812
—
—
—
—
Osmolality of Urine
2695-5 [3026782]
—
—
—
—
—
—
6.1e-01
—
—
—
—
—
—
—
—
—
—
—
—
cases:4.55%
controls:2.53%
—
—
—
—
—
—
7
41
147
1582
rosiglitazone; oral
A10BG02 [21600781]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.37%
—
—
—
—
—
—
0
6
154
1617
Acute maxillary sinusitis
J01.0 [45601112]
-1.2e-01
-1.0e+50
—
—
—
—
1.1e+00
cases:2.75%
controls:3.08%
cases:0.00%
controls:0.77%
—
—
—
—
—
—
—
—
cases:6.49%
controls:2.28%
5
56
177
1761
0
14
182
1803
—
—
—
—
10
37
144
1586
Transurethral resection of prostate
KED22 [2001306138]
—
-1.0e+50
—
—
—
—
-1.0e+50
—
—
cases:0.00%
controls:0.28%
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.55%
—
0
5
182
1812
—
—
—
—
0
9
154
1614
Rheumatoid/seropositive arthritis
L88 [2002000707]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.33%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
182
1811
—
—
—
—
—
—
Panorama tomography of teeth and jaws or similar X-ray examination
EB1HA [2001301913]
2.6e-01
1.2e+00
—
—
—
—
4.3e-01
cases:4.95%
controls:3.85%
cases:2.75%
controls:0.88%
—
—
—
—
—
—
—
—
cases:6.49%
controls:4.31%
9
70
173
1747
5
16
177
1801
—
—
—
—
10
70
144
1553
phenylpropanolamine, combinations; oral
R01BA51 [21603212]
6.3e-01
—
—
—
—
—
6.4e-01
cases:4.95%
controls:2.70%
—
—
—
—
—
—
—
—
—
—
cases:3.90%
controls:2.09%
9
49
173
1768
—
—
—
—
—
6
34
148
1589
phenylephrine, combinations
R01BA53 [21603214]
1.8e-01
—
—
—
-1.0e+50
—
4.2e-01
cases:4.40%
controls:3.69%
—
—
—
—
—
—
cases:0.00%
controls:0.28%
—
—
cases:4.55%
controls:3.02%
8
67
174
1750
—
—
—
0
5
181
1810
—
7
49
147
1574
pimecrolimus
D11AH02 [21602339]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.80%
—
—
—
—
—
—
0
13
154
1610
androstanolone
A14AA01 [21600917]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.31%
—
—
—
—
—
—
0
5
154
1618
Surface analgesia on skin or mucosa
WX105 [2001310765]
—
-1.0e+50
—
—
—
-1.0e+50
—
—
—
cases:0.00%
controls:0.28%
—
—
—
—
—
—
cases:0.00%
controls:0.28%
—
—
—
0
5
182
1812
—
—
—
0
5
173
1776
—
Chronic obstructive pulmonary disease with acute lower respiratory infection
J44.0 [45601131]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.28%
—
—
—
—
—
—
—
—
—
—
—
0
5
182
1812
—
—
—
—
—
CBC W Ordered Manual Differential panel - Blood
57782-5 [40760892]
4.5e-01
1.2e+00
—
—
—
—
2.6e-01
cases:3.85%
controls:2.48%
cases:3.85%
controls:1.16%
—
—
—
—
—
—
—
—
cases:5.19%
controls:4.07%
7
45
175
1772
7
21
175
1796
—
—
—
—
8
66
146
1557
insulin degludec; parenteral
A10AE06 [43534747]
-1.0e+50
-1.0e+50
—
—
—
-1.0e+50
—
cases:0.00%
controls:0.28%
cases:0.00%
controls:0.39%
—
—
—
—
—
—
cases:0.00%
controls:0.45%
—
—
0
5
182
1812
0
7
182
1810
—
—
—
0
8
173
1773
—
Injection therapy, other than intramuscular or subcutaneous
SPAT1203 [2001700304]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.39%
—
—
—
—
—
—
—
—
—
—
—
—
0
7
182
1810
—
—
—
—
—
—
Cutaneous abscess, furuncle and carbuncle
L02 [45538561]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.49%
—
—
—
—
—
—
0
8
154
1615
False labour at or after 37 completed weeks of gestation
O47.1 [45558317]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.33%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
182
1811
—
—
—
—
—
—
Exercise ECG
SPAT1098 [2001700199]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.31%
—
—
—
—
—
—
0
5
154
1618
Endocr/metab/nutr sympt/compl other
T29 [2002001077]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.28%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
182
1812
—
—
—
—
—
—
cefadroxil; oral
J01DB05 [21602874]
5.2e-01
—
—
—
—
-1.0e+50
—
cases:3.85%
controls:2.31%
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.56%
—
—
7
42
175
1775
—
—
—
—
0
10
173
1771
—
baclofen; oral, parenteral
M03BX01 [21604115]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.28%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.37%
0
5
182
1812
—
—
—
—
—
0
6
154
1617
Influenza virus B RNA [Presence] in Specimen by NAA with probe detection
40982-1 [3038288]
—
-1.0e+50
—
—
—
-1.0e+50
—
—
—
cases:0.00%
controls:0.39%
—
—
—
—
—
—
cases:0.00%
controls:0.45%
—
—
—
0
7
182
1810
—
—
—
0
8
173
1773
—
Obesity due to excess calories
E66.01 [2000501501]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.56%
—
—
—
—
—
—
—
0
10
173
1771
—
Hepatitis B virus core IgM Ab [Presence] in Serum
31204-1 [3013527]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.28%
—
—
—
—
—
—
—
—
—
—
—
0
5
182
1812
—
—
—
—
—
levetiracetam; oral, parenteral
N03AX14 [21604436]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.43%
—
—
—
—
—
—
0
7
154
1616
glucosamine; oral
M01AX05 [21604002]
1.9e-01
—
-1.0e+50
—
-1.0e+50
—
-1.1e-01
cases:3.85%
controls:3.19%
—
—
cases:0.00%
controls:0.33%
—
—
cases:0.00%
controls:0.33%
—
—
cases:4.55%
controls:5.05%
7
58
175
1759
—
0
6
182
1811
—
0
6
181
1809
—
7
82
147
1541
Coxarthrosis [arthrosis of hip]
M16 [45577162]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.28%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.31%
0
5
182
1812
—
—
—
—
—
0
5
154
1618
fusidic acid; ointment
D06AX01 [21602062]
7.2e-01
—
—
—
—
-1.0e+50
3.4e-02
cases:4.95%
controls:2.48%
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.79%
cases:3.25%
controls:3.14%
9
45
173
1772
—
—
—
—
0
14
173
1767
5
51
149
1572
betaxolol; oral
C07AB05 [21601687]
—
—
-1.0e+50
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.39%
—
—
—
—
—
—
—
—
—
—
0
7
182
1810
—
—
—
—
Lactate [Moles/volume] in Blood
32693-4 [3047181]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.39%
—
—
—
—
—
—
—
—
—
—
—
—
0
7
182
1810
—
—
—
—
—
—
Biopsy of vulva or perineum
LFB00 [2001306759]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.28%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.43%
0
5
182
1812
—
—
—
—
—
0
7
154
1616
Human metapneumovirus RNA [Presence] in Specimen by NAA with probe detection
38917-1 [3042194]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.28%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
182
1812
—
—
—
—
—
—
Benzodiazepines [Presence] in Urine
3390-2 [3000764]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.44%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.43%
0
8
182
1809
—
—
—
—
—
0
7
154
1616
Natriuretic peptide.B prohormone N-Terminal [Mass/volume] in Serum or Plasma
33762-6 [3029187]
1.2e+00
1.4e+00
—
—
—
1.1e+00
4.8e-01
cases:4.95%
controls:1.54%
cases:4.40%
controls:1.16%
—
—
—
—
—
—
cases:4.05%
controls:1.35%
cases:5.84%
controls:3.70%
9
28
173
1789
8
21
174
1796
—
—
—
7
24
166
1757
9
60
145
1563
Asthma
R96 [2002000961]
—
-1.0e+50
—
—
—
-1.0e+50
—
—
—
cases:0.00%
controls:0.44%
—
—
—
—
—
—
cases:0.00%
controls:0.45%
—
—
—
0
8
182
1809
—
—
—
0
8
173
1773
—
Exploration of joint of shoulder or upper arm, arthroscopic
NBA30 [2001307269]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.33%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.31%
0
6
182
1811
—
—
—
—
—
0
5
154
1618
Follow-up examination after treatment of fracture
Z09.4 [45561611]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.39%
—
—
—
—
—
—
—
—
—
—
—
—
0
7
182
1810
—
—
—
—
—
—
lansoprazole; oral
A02BC03 [21600098]
6.1e-01
1.1e+00
—
—
—
4.2e-01
3.3e-01
cases:7.14%
controls:4.02%
cases:4.40%
controls:1.54%
—
—
—
—
—
—
cases:2.89%
controls:1.91%
cases:6.49%
controls:4.74%
13
73
169
1744
8
28
174
1789
—
—
—
5
34
168
1747
10
77
144
1546
pindolol; oral, parenteral
C07AA03 [21601669]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.28%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
182
1812
—
—
—
—
—
—
clindamycin
D10AF01 [21602305]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.83%
—
—
—
—
—
—
—
—
—
—
—
—
0
15
182
1802
—
—
—
—
—
—
Outcome of delivery
Z37 [45581024]
-6.2e-01
—
—
—
—
—
—
cases:2.75%
controls:5.01%
—
—
—
—
—
—
—
—
—
—
—
—
5
91
177
1726
—
—
—
—
—
—
valsartan and diuretics
C09DA03 [21601836]
—
—
-1.0e+50
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.33%
—
—
—
—
—
—
—
—
—
—
0
6
182
1811
—
—
—
—
oxazepam; oral
N05BA04 [21604569]
-3.5e-01
1.1e-01
—
—
—
1.4e-01
—
cases:2.75%
controls:3.85%
cases:2.75%
controls:2.48%
—
—
—
—
—
—
cases:2.89%
controls:2.53%
—
—
5
70
177
1747
5
45
177
1772
—
—
—
5
45
168
1736
—
Routine postpartum follow-up
Z39.2 [45547306]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:1.93%
—
—
—
—
—
—
—
—
—
—
—
—
0
35
182
1782
—
—
—
—
—
—
Casts [#/volume] in Urine by Automated count
51483-6 [3030467]
6.2e-02
—
—
—
—
1.0e+00
1.6e-01
cases:2.75%
controls:2.59%
—
—
—
—
—
—
—
—
cases:2.89%
controls:1.07%
cases:4.55%
controls:3.88%
5
47
177
1770
—
—
—
—
5
19
168
1762
7
63
147
1560
propranolol and thiazides
C07BA05 [21601704]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.39%
—
—
—
—
—
—
—
—
—
—
—
—
0
7
182
1810
—
—
—
—
—
—
Monitored bed care
WX892 [2001310850]
-1.0e+50
—
—
—
—
-1.0e+50
—
cases:0.00%
controls:0.33%
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.28%
—
—
0
6
182
1811
—
—
—
—
0
5
173
1776
—
Naevus/mole
S82 [2002001046]
1.2e+00
—
—
—
—
—
—
cases:3.30%
controls:0.99%
—
—
—
—
—
—
—
—
—
—
—
—
6
18
176
1799
—
—
—
—
—
—
Familial hypercholesterolaemia
E78.00 [2000501513]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.28%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.37%
0
5
182
1812
—
—
—
—
—
0
6
154
1617
Contusion of other parts of wrist and hand
S60.2 [45602941]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.33%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.49%
0
6
182
1811
—
—
—
—
—
0
8
154
1615
Anogenital (venereal) warts
A63.0 [45585929]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.39%
—
—
—
—
—
—
—
—
—
—
—
—
0
7
182
1810
—
—
—
—
—
—
vilanterol and fluticasone furoate
R03AK10 [43534841]
-1.0e+50
-1.0e+50
—
—
—
-1.0e+50
—
cases:0.00%
controls:0.33%
cases:0.00%
controls:0.33%
—
—
—
—
—
—
cases:0.00%
controls:0.51%
—
—
0
6
182
1811
0
6
182
1811
—
—
—
0
9
173
1772
—
Adenovirus DNA [Identifier] in Specimen by NAA with probe detection
40976-3 [3040853]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.28%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
182
1812
—
—
—
—
—
—
Examination for driving licence
Z02.4 [45552056]
7.8e-01
—
—
—
—
—
3.6e-01
cases:3.30%
controls:1.54%
—
—
—
—
—
—
—
—
—
—
cases:4.55%
controls:3.20%
6
28
176
1789
—
—
—
—
—
7
52
147
1571
Other minor procedure on skin
TQW99 [2001310150]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.44%
—
—
—
—
—
—
—
—
—
—
—
—
0
8
182
1809
—
—
—
—
—
—
Pharmacological induction or advancement of labor
MAC40 [2001306872]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.28%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
182
1812
—
—
—
—
—
—
Metamyelocytes/Leukocytes in Blood
28541-1 [3002179]
—
—
—
—
—
—
1.3e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:3.25%
controls:0.92%
—
—
—
—
—
—
5
15
149
1608
acrivastine; oral
R06AX18 [21603518]
1.4e-01
4.4e-01
—
—
-1.0e+50
6.8e-01
7.4e-02
cases:9.34%
controls:8.26%
cases:4.95%
controls:3.25%
—
—
—
—
cases:0.00%
controls:0.44%
cases:6.36%
controls:3.31%
cases:8.44%
controls:7.89%
17
150
165
1667
9
59
173
1758
—
—
0
8
181
1807
11
59
162
1722
13
128
141
1495
Limited function/disability NOS
A28 [2002000162]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.55%
—
—
—
—
—
—
—
—
—
—
—
—
0
10
182
1807
—
—
—
—
—
—
formoterol and beclometasone
R03AK08 [43534839]
-1.0e+50
-1.0e+50
—
—
—
-1.0e+50
—
cases:0.00%
controls:0.33%
cases:0.00%
controls:0.28%
—
—
—
—
—
—
cases:0.00%
controls:0.39%
—
—
0
6
182
1811
0
5
182
1812
—
—
—
0
7
173
1774
—
lipegfilgrastim; parenteral
L03AA14 [43534819]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.28%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
182
1812
—
—
—
—
—
—
Infected finger/toe
S09 [2002000974]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.55%
—
—
—
—
—
—
0
9
154
1614
Angina pectoris
I20 [45572078]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.68%
—
—
—
—
—
—
0
11
154
1612
Excision of skin or mucous membrane lesion
SPAT1141 [2001700242]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.43%
—
—
—
—
—
—
0
7
154
1616
Breast Pathology biopsy report
66110-8 [40768793]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.39%
—
—
—
—
—
—
—
—
—
—
—
—
0
7
182
1810
—
—
—
—
—
—
Release of median nerve
ACC51 [2001300642]
—
-1.0e+50
—
—
—
—
-1.0e+50
—
—
cases:0.00%
controls:0.44%
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.68%
—
0
8
182
1809
—
—
—
—
0
11
154
1612
acetylcysteine; inhalant, oral
R05CB01 [21603380]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.33%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
182
1811
—
—
—
—
—
—
hypromellose
S01KA02 [21605115]
—
—
—
—
—
—
4.2e-01
—
—
—
—
—
—
—
—
—
—
—
—
cases:3.25%
controls:2.16%
—
—
—
—
—
—
5
35
149
1588
bisoprolol and thiazides
C07BB07 [21601714]
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.28%
—
—
—
—
—
—
—
—
0
5
181
1810
—
—
oxycodone and naloxone; oral
N02AA55 [21604265]
—
-1.0e+50
—
—
—
—
9.3e-01
—
—
cases:0.00%
controls:0.33%
—
—
—
—
—
—
—
—
cases:4.55%
controls:1.85%
—
0
6
182
1811
—
—
—
—
7
30
147
1593
Total cardiopulmonary bypass in normothermia or moderate hypothermia at concurrent surgical procedure
FXA00 [2001303347]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.31%
—
—
—
—
—
—
0
5
154
1618
Pain in joint
M25.5 [45586941]
1.1e-01
—
—
—
—
—
5.8e-01
cases:3.30%
controls:2.97%
—
—
—
—
—
—
—
—
—
—
cases:7.79%
controls:4.50%
6
54
176
1763
—
—
—
—
—
12
73
142
1550
Sinus symptom/complaint
R09 [2002000890]
-1.0e+50
-1.0e+50
—
—
—
—
—
cases:0.00%
controls:0.88%
cases:0.00%
controls:0.39%
—
—
—
—
—
—
—
—
—
—
0
16
182
1801
0
7
182
1810
—
—
—
—
—
Lumbago with sciatica
M54.4 [45553205]
7.1e-01
—
—
—
—
—
—
cases:2.75%
controls:1.38%
—
—
—
—
—
—
—
—
—
—
—
—
5
25
177
1792
—
—
—
—
—
—
Headache
N01 [2002000720]
—
-1.0e+50
—
—
—
—
-1.0e+50
—
—
cases:0.00%
controls:0.28%
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.74%
—
0
5
182
1812
—
—
—
—
0
12
154
1611
Iridotomy
CHC05 [2001301259]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.31%
—
—
—
—
—
—
0
5
154
1618
azelastine; nasal
R01AC03 [21605035]
4.9e-01
—
-1.0e+50
—
—
—
9.9e-01
cases:4.40%
controls:2.75%
—
—
cases:0.00%
controls:0.39%
—
—
—
—
—
—
cases:8.44%
controls:3.33%
8
50
174
1767
—
0
7
182
1810
—
—
—
13
54
141
1569
Coagulation factor VIII activity actual/normal in Platelet poor plasma by Coagulation assay
3209-4 [3019250]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.33%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
182
1811
—
—
—
—
—
—
Prostate Specific Ag Free/Prostate specific Ag.total in Serum or Plasma
12841-3 [3001784]
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.28%
—
—
—
—
—
—
—
—
0
5
181
1810
—
—
cefalexin; oral
J01DB01 [21602870]
2.7e-01
6.8e-01
—
—
1.1e+00
2.3e-01
2.5e-01
cases:31.87%
controls:26.25%
cases:15.38%
controls:8.42%
—
—
—
—
cases:3.31%
controls:1.10%
cases:10.40%
controls:8.48%
cases:32.47%
controls:27.30%
58
477
124
1340
28
153
154
1664
—
—
6
20
175
1795
18
151
155
1630
50
443
104
1180
Functional dysphonia
R49.01 [2000503597]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.28%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.43%
0
5
182
1812
—
—
—
—
—
0
7
154
1616
dexamethasone and antiinfectives
S02CA06 [21605178]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.45%
—
—
—
—
—
—
—
0
8
173
1773
—
Low back pain
M54.5 [45553207]
4.0e-01
—
—
—
—
5.0e-01
6.8e-01
cases:6.04%
controls:4.13%
—
—
—
—
—
—
—
—
cases:3.47%
controls:2.13%
cases:9.74%
controls:5.18%
11
75
171
1742
—
—
—
—
6
38
167
1743
15
84
139
1539
Alzheimer disease, unspecified
G30.9 [45591165]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.62%
—
—
—
—
—
—
0
10
154
1613
dydrogesterone; oral
G03DB01 [21602544]
—
—
—
—
—
—
1.1e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:3.25%
controls:1.11%
—
—
—
—
—
—
5
18
149
1605
Aortic (valve) stenosis
I35.0 [45576869]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.55%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.99%
0
10
182
1807
—
—
—
—
—
0
16
154
1607
Hemoglobin [Presence] in Urine by Test strip
5794-3 [3011397]
1.8e-01
6.7e-01
—
—
—
—
1.8e-01
cases:2.75%
controls:2.31%
cases:3.30%
controls:1.71%
—
—
—
—
—
—
—
—
cases:5.19%
controls:4.37%
5
42
177
1775
6
31
176
1786
—
—
—
—
8
71
146
1552
Irritable bowel syndrome
K58 [45572218]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.28%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.37%
0
5
182
1812
—
—
—
—
—
0
6
154
1617
Vascular Surgery
77 [38004496]
6.3e-01
—
—
—
—
—
2.9e-01
cases:3.85%
controls:2.09%
—
—
—
—
—
—
—
—
—
—
cases:3.90%
controls:2.96%
7
38
175
1779
—
—
—
—
—
6
48
148
1575
Acute sinusitis, unspecified
J01.9 [45543252]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.39%
—
—
—
—
—
—
—
—
—
—
—
—
0
7
182
1810
—
—
—
—
—
—
Ankle symptom/complaint
L16 [2002000640]
—
—
—
—
—
—
1.4e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:3.25%
controls:0.80%
—
—
—
—
—
—
5
13
149
1610
Vaginal enterocele
N81.5 [45606507]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.28%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
182
1812
—
—
—
—
—
—
Leukocytes [Presence] in Urine
33052-2 [3045414]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.34%
—
—
—
—
—
—
—
0
6
173
1775
—
Bicarbonate [Moles/volume] in Arterial blood
1960-4 [3008152]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.23%
—
—
—
—
—
—
0
20
154
1603
dexbrompheniramine, combinations
R06AB56 [21603469]
-1.0e+50
-1.0e+50
—
—
—
-1.0e+50
—
cases:0.00%
controls:0.99%
cases:0.00%
controls:0.28%
—
—
—
—
—
—
cases:0.00%
controls:0.45%
—
—
0
18
182
1799
0
5
182
1812
—
—
—
0
8
173
1773
—
Erythrocytes [Presence] in Urine
33051-4 [3045424]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.28%
—
—
—
—
—
—
—
0
5
173
1776
—
allopurinol; oral, parenteral
M04AA01 [21604131]
1.0e+00
1.2e+00
—
—
—
9.7e-01
7.7e-01
cases:4.40%
controls:1.60%
cases:3.85%
controls:1.16%
—
—
—
—
—
—
cases:3.47%
controls:1.35%
cases:4.55%
controls:2.16%
8
29
174
1788
7
21
175
1796
—
—
—
6
24
167
1757
7
35
147
1588
combinations of corticosteroids
D07XB30 [21602188]
-1.0e-01
7.6e-01
—
—
—
-1.4e-01
6.2e-01
cases:9.34%
controls:10.24%
cases:6.59%
controls:3.19%
—
—
—
—
—
—
cases:2.89%
controls:3.31%
cases:16.23%
controls:9.43%
17
186
165
1631
12
58
170
1759
—
—
—
5
59
168
1722
25
153
129
1470
metoprolol; oral, parenteral
C07AB02 [21601684]
-1.9e-01
8.3e-02
—
—
—
-2.1e-02
1.6e-01
cases:4.95%
controls:5.94%
cases:4.95%
controls:4.57%
—
—
—
—
—
—
cases:4.62%
controls:4.72%
cases:7.79%
controls:6.72%
9
108
173
1709
9
83
173
1734
—
—
—
8
84
165
1697
12
109
142
1514
Chronic glaucoma with open ventricular angle
H40.13 [2000502335]
—
-1.0e+50
—
—
—
-1.0e+50
-1.0e+50
—
—
cases:0.00%
controls:0.55%
—
—
—
—
—
—
cases:0.00%
controls:0.51%
cases:0.00%
controls:1.23%
—
0
10
182
1807
—
—
—
0
9
173
1772
0
20
154
1603
metronidazole; oral, rectal
P01AB01 [21604857]
-5.8e-02
—
—
—
—
4.2e-01
-6.3e-01
cases:6.04%
controls:6.38%
—
—
—
—
—
—
—
—
cases:2.89%
controls:1.91%
cases:3.90%
controls:7.09%
11
116
171
1701
—
—
—
—
5
34
168
1747
6
115
148
1508
Extractable nuclear Ab panel - Serum
43119-7 [3029075]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.33%
—
—
—
—
—
—
—
—
—
—
—
0
6
182
1811
—
—
—
—
—

LabWAS

↥
OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
36
125
3.31
8.57
4.3
2.3
47.54
40.83
u/ml
0.15
36
119
49
206
2.85
8.39
3.3
4.3
5.05
9.02
ug/l
0.77
35
162
88
560
2.05
5.56
3.7
2.2
—
—
—
0
0
111
793
1.94
4.81
3.7
2.7
—
—
estimate
—
0
0
9
14
6.68
4.03
3.8
3.0
5.08
3.76
nmol/l
—
9
14
11
25
4.60
3.68
1.1
1.4
2.99
9.04
u/ml
0.52
11
25
108
811
1.75
3.58
14.0
12.7
1.17
1.22
inr
0.46
96
664
46
267
1.95
3.55
3.2
2.9
3.55
3.01
e6/l
0.14
27
132
66
435
1.79
3.41
3.2
2.8
327.75
331.10
umol/l
0.09
59
376
121
950
1.73
3.32
9.2
6.2
11.25
11.01
umol/l
0.11
111
898
123
977
1.71
3.17
11.8
10.5
4.36
4.03
e9/l
0.59
99
859
17
68
2.64
3.14
3.4
3.3
—
—
—
0
0
26
128
2.19
3.09
8.1
5.2
9.93
10.07
mmol/l
0.03
26
119
96
722
1.66
2.98
2.4
2.1
—
—
—
0
0
59
395
1.71
2.82
1.7
1.7
1.01
1.27
mg/l
0.43
44
326
53
350
1.71
2.65
1.3
1.3
12.46
28.19
iu/ml
1.95
13
110
39
236
1.82
2.62
1.3
1.3
—
—
—
0
0
7
15
4.80
2.62
2.3
1.3
—
—
—
0
0
100
778
1.59
2.59
9.5
5.8
1.20
1.21
mmol/l
0.59
93
715
111
886
1.60
2.58
8.1
5.8
1.96
1.92
e9/l
0.15
96
785
24
124
2.07
2.54
2.6
2.4
—
—
—
0
0
68
489
1.60
2.42
3.9
3.9
—
—
—
0
0
64
457
1.60
2.33
3.0
2.2
2.61
2.95
mg/l
0.69
58
393
107
861
1.54
2.30
8.2
5.8
0.59
0.58
e9/l
0.23
90
742
6
13
4.73
2.29
2.0
1.2
—
—
—
0
0
150
1306
1.67
2.27
12.4
7.8
87.18
78.98
u/l
0.75
142
1228
13
54
2.51
2.25
1.9
1.3
205.13
291.75
ug/g
—
8
31
130
1097
1.57
2.22
5.1
3.3
58.72
44.65
u/l
0.67
124
1036
107
868
1.52
2.17
8.2
5.7
0.04
0.04
e9/l
0.20
90
744
6
14
4.39
2.17
1.0
1.1
—
—
—
0
0
28
163
1.84
2.13
1.5
1.4
—
—
—
0
0
8
25
3.29
2.12
1.3
1.0
—
—
—
0
0
8
26
3.16
2.03
2.1
1.4
—
—
—
0
0
45
307
1.61
1.95
1.3
1.3
14.15
9.02
u/ml
0.17
23
111
100
814
1.47
1.91
8.8
6.0
27.25
27.46
%
0.06
95
772
8
28
2.94
1.88
2.0
1.5
—
—
—
0
0
26
154
1.80
1.88
4.7
4.0
7.38
7.36
ph
0.74
18
102
74
570
1.48
1.85
9.7
5.1
—
—
—
0
0
11
48
2.37
1.74
3.1
2.3
122.20
10237.35
u/l
—
5
20
30
190
1.69
1.73
7.0
7.6
0.07
1.02
mmol/l
0.85
25
166
23
137
1.77
1.64
11.4
8.3
—
—
—
0
0
107
899
1.43
1.64
8.9
6.2
0.20
0.18
e9/l
0.36
94
788
10
43
2.40
1.61
1.0
1.2
—
—
—
0
0
83
668
1.43
1.61
4.6
3.8
79.06
39.42
ng/l
0.60
61
469
97
803
1.42
1.60
9.4
6.0
8.92
8.86
%
0.07
90
751
24
146
1.74
1.60
1.2
1.1
—
—
—
0
0
6
20
3.06
1.59
1.8
1.0
—
—
—
0
0
56
422
1.46
1.53
2.9
3.9
—
0.25
—
0
8
29
190
1.62
1.48
7.2
7.7
7.41
7.43
ph
0.70
13
110
102
863
1.39
1.43
9.8
6.3
1.21
1.21
mmol/l
0.36
89
740
31
209
1.58
1.41
1.2
1.3
—
—
—
0
0
5
17
2.99
1.36
2.6
2.7
—
—
—
0
0
95
800
1.37
1.35
9.5
5.9
0.82
0.68
%
2.27
90
745
95
801
1.37
1.34
9.4
5.8
3.29
2.69
%
1.28
90
750
79
651
1.36
1.27
5.0
4.0
33.85
73.21
e6/l
1.12
52
454
15
86
1.81
1.23
1.4
1.2
—
—
—
0
0
69
561
1.36
1.20
4.5
3.2
17.07
170.77
e6/l
0.73
51
430
35
253
1.47
1.18
3.2
2.0
—
—
—
0
0
32
228
1.48
1.15
11.8
6.4
105.81
104.52
mmol/l
1.51
32
228
48
372
1.39
1.11
1.9
1.8
239535304.16
470.80
pmol/l
0.49
43
310
5
21
2.42
1.09
1.0
1.0
—
—
—
0
0
170
1600
1.52
1.09
25.5
16.0
25.52
23.30
mg/l
0.39
152
1335
163
1523
1.45
1.07
7.0
5.7
2.07
1.93
mu/l
0.25
154
1397
107
942
1.30
1.03
4.3
4.1
0.18
0.00
estimate
0.48
17
183
9
48
1.92
1.02
1.0
1.2
—
86.25
—
0
8
5
23
2.20
0.98
1.0
1.2
—
—
nmol/l
—
0
0
141
1294
1.33
0.98
5.8
4.6
14.94
14.77
pmol/l
0.37
131
1179
15
93
1.66
0.97
5.3
4.3
—
—
—
0
0
86
741
1.29
0.96
3.6
3.6
6.23
6.21
ph
0.05
41
394
7
37
1.92
0.95
3.7
2.8
—
—
—
0
0
9
52
1.77
0.94
2.0
2.3
1.52
1.45
mg/l
—
9
44
9
52
1.77
0.94
2.7
2.9
—
—
—
0
0
172
1634
1.48
0.92
19.4
14.3
—
—
—
0
0
104
924
1.27
0.89
4.3
4.0
0.00
0.00
estimate
-0.00
16
195
58
484
1.28
0.81
4.7
3.1
0.67
0.51
e6/l
0.19
41
351
64
545
1.26
0.76
1.9
1.7
19.31
21.37
nmol/l
0.52
56
447
49
412
1.25
0.64
1.4
1.3
0.58
1.88
u/ml
1.39
13
112
5
29
1.74
0.64
1.2
1.4
—
—
—
0
0
16
113
1.45
0.63
1.3
1.3
—
—
—
0
0
21
157
1.38
0.62
2.2
2.7
5.89
6.11
ph
0.59
14
104
0
21
0.00
0.60
0.0
2.5
—
—
—
0
0
22
167
1.36
0.60
1.7
1.4
—
—
—
0
0
32
258
1.29
0.59
1.2
1.2
—
—
—
0
0
16
115
1.43
0.59
1.2
1.2
323.16
142.37
u/ml
—
8
42
10
147
0.66
0.56
10.3
3.6
—
—
—
0
0
47
401
1.23
0.54
3.7
4.2
1.02
1.02
kg/l
0.18
30
260
102
937
1.19
0.54
4.3
4.0
0.00
8.12
estimate
0.50
16
200
37
308
1.25
0.53
2.3
1.7
1244.67
1214.30
nmol/l
0.07
27
233
6
39
1.56
0.53
1.0
1.3
—
—
—
0
0
59
519
1.20
0.51
8.8
6.5
—
—
—
0
0
79
716
1.17
0.48
1.8
2.0
1.45
1.31
mmol/l
0.50
67
592
5
82
0.60
0.47
1.4
2.2
—
—
—
0
0
5
84
0.58
0.46
1.8
1.7
—
—
—
0
0
84
767
1.17
0.46
2.5
2.2
102.97
98.72
pmol/l
0.24
43
375
20
158
1.30
0.44
8.8
3.2
7.39
7.39
ph
—
9
89
39
335
1.21
0.43
3.8
2.9
505.62
515.80
mosm/kgh2o
0.09
29
297
8
58
1.40
0.42
2.1
4.8
135.50
169.19
mg/l
—
8
48
8
58
1.40
0.42
2.1
4.8
24.00
65.37
mg/l
—
8
48
44
384
1.19
0.41
1.8
1.4
2.01
2.57
g/l
0.95
24
227
0
17
0.00
0.41
0.0
17.6
—
904.53
—
0
17
0
18
0.00
0.40
0.0
1.1
—
262.67
—
0
12
19
152
1.28
0.38
5.3
5.1
0.86
0.85
%
—
7
48
18
143
1.29
0.38
5.3
5.2
0.00
0.10
%
—
6
39
45
507
0.85
0.38
5.4
3.5
0.00
0.00
estimate
-0.00
14
152
43
380
1.17
0.35
2.5
2.8
2.45
2.46
mmol/l
0.09
38
341
177
1731
1.27
0.35
37.1
24.9
6.99
6.64
e9/l
1.14
172
1684
177
1731
1.27
0.35
37.0
24.8
4.33
4.41
e12/l
1.55
172
1685
40
352
1.17
0.34
4.5
3.9
306.51
267.47
ng/l
0.06
35
278
63
579
1.13
0.30
3.4
3.1
—
—
—
0
0
18
148
1.24
0.30
5.4
5.8
0.00
0.03
%
—
6
36
157
1525
1.16
0.30
6.9
6.4
39.08
39.22
mmol/mol
0.08
149
1436
58
532
1.13
0.29
7.6
3.8
7.40
7.40
ph
0.32
39
379
11
86
1.30
0.27
7.0
2.3
0.50
0.61
%
0.83
11
86
161
1571
1.15
0.26
5.6
5.3
5.77
5.91
mmol/l
0.75
152
1443
16
133
1.22
0.25
2.3
2.4
0.14
1.21
e6/l
0.82
16
125
55
594
0.90
0.25
3.1
3.4
—
—
—
0
0
11
87
1.28
0.25
7.0
2.4
0.89
1.15
%
0.68
11
87
5
37
1.36
0.23
2.2
1.6
—
—
—
0
0
162
1585
1.14
0.22
5.4
5.3
4.62
4.69
mmol/l
0.39
155
1468
0
11
0.00
0.21
0.0
7.2
—
8.72
—
0
11
0
11
0.00
0.21
0.0
2.5
—
498.00
—
0
6
0
12
0.00
0.21
0.0
2.6
—
623.17
—
0
6
5
43
1.17
0.21
10.6
4.0
—
—
—
0
0
0
13
0.00
0.21
0.0
1.7
—
68.85
—
0
13
22
193
1.16
0.20
2.1
1.6
—
—
—
0
0
12
143
0.83
0.19
4.0
4.1
1.22
1.22
mmol/l
0.15
12
123
41
378
1.11
0.19
3.9
2.7
6.14
5.53
e6/l
0.15
34
350
13
110
1.19
0.17
1.3
1.8
—
—
—
0
0
56
528
1.09
0.17
4.3
3.9
0.00
0.01
estimate
0.50
15
180
25
275
0.90
0.15
1.8
1.8
—
—
—
0
0
16
140
1.16
0.15
6.0
5.3
0.50
0.78
%
—
6
39
12
102
1.19
0.15
1.3
1.2
—
—
—
0
0
13
113
1.16
0.13
2.0
1.3
—
—
—
0
0
38
403
0.93
0.12
5.9
5.2
—
—
—
0
0
67
696
0.94
0.11
4.9
4.0
0.07
0.02
estimate
0.30
15
158
25
231
1.09
0.11
2.0
1.5
—
—
—
0
0
6
57
1.05
0.08
1.2
1.2
—
—
—
0
0
75
769
0.96
0.07
15.3
11.4
0.00
0.00
e9/l
1.26
55
627
23
216
1.07
0.07
1.4
1.4
—
—
—
0
0
45
467
0.95
0.07
1.6
1.4
—
—
—
0
0
151
1498
1.04
0.04
4.6
4.4
1.25
1.25
mmol/l
0.00
142
1375
159
1579
1.04
0.04
5.2
5.2
1.51
1.53
mmol/l
0.31
151
1458
160
1607
0.97
0.01
6.2
6.1
2.65
2.73
mmol/l
0.55
152
1484
15
144
1.05
0.00
1.3
1.4
—
—
—
0
0
55
546
1.01
0.00
4.5
3.9
13.82
7.72
mg/mmol
0.48
31
308
57
567
1.01
0.00
3.4
3.0
6.94
7.16
mmol/l
0.17
45
465
54
545
0.99
0.00
3.7
3.1
76.43
47.95
mg/l
0.35
33
325
16
162
0.99
0.00
1.3
1.5
—
—
—
0
0
5
55
0.91
0.00
14.4
10.4
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.4
—
—
—
0
0
0
8
0.00
-0.00
0.0
1.0
—
0.00
—
0
8
0
5
0.00
-0.00
0.0
1.2
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.1
—
—
—
0
0
8
80
1.00
-0.00
3.0
2.5
—
—
—
0
0
0
9
0.00
-0.00
0.0
1.0
—
—
—
0
0
6
64
0.94
-0.00
1.0
1.1
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.1
—
229.43
—
0
7
0
8
0.00
-0.00
0.0
1.1
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.2
—
1.21
—
0
5
0
8
0.00
-0.00
0.0
1.3
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.5
—
—
—
0
0
0
7
0.00
-0.00
0.0
3.4
—
0.86
—
0
7
0
9
0.00
-0.00
0.0
1.0
—
—
—
0
0

Mortality – FinRegistry

↥

Association

Association between endpoint CD2_BENIGN_RETROPERITONEUM_PERITONEUM and mortality.

Females

Parameter HR [95% CI] p-value
CD2_BENIGN_RETROPERITONEUM_PERITONEUM 2.385 [1.89, 3.01] < 0.001
Birth year 0.993 [0.98, 1.0] 0.1

During the follow-up period (1.1.1998 — 31.12.2019), 150 out of 605 females with CD2_BENIGN_RETROPERITONEUM_PERITONEUM died.

Males

Parameter HR [95% CI] p-value
CD2_BENIGN_RETROPERITONEUM_PERITONEUM 1.881 [1.45, 2.44] < 0.001
Birth year 0.987 [0.98, 1.0] 0.007

During the follow-up period (1.1.1998 — 31.12.2019), 136 out of 336 males with CD2_BENIGN_RETROPERITONEUM_PERITONEUM died.

Mortality risk

Mortality risk for people of age

years, who have CD2_BENIGN_RETROPERITONEUM_PERITONEUM.

N-year risk Females Males
1 0.204% 0.449%
5 1.191% 2.385%
10 3.436% 5.42%
15 6.315% 9.864%
20 10.745% 16.087%

Relationships between endpoints

↥

Index endpoint: CD2_BENIGN_RETROPERITONEUM_PERITONEUM – Benign neoplasm of soft tissue of retroperitoneum and peritoneum

GWS hits: -

Endpoint
Case Overlap
Survival Analysis
Genetic Correlations
Genetic Signals
N (Jaccard index)
HR [CI]
rg [CI]
Hits
Coloc Hits
FinRegistry
FinnGen
FinRegistry
FinnGen
FinnGen
loading spinner Loading data